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 Breast cancer is the most common malignancy in women worldwide, and over 40,000 
people die from breast cancer each year in the US alone. Further, metastasis, the spread of 
tumor cells and the colonization of distant sites, remains challenging to treat. The cancer stem 
cell (CSC) hypothesis proposes that not all tumor cells are capable of initiating new tumors 
or indeterminate growth. Instead, only a subset, the CSCs, are the drivers of metastasis. 
Recently, thioridazine, an antipsychotic drug that primarily target dopamine receptor 2 
(DRD2) were shown to inhibit certain properties of CSCs, such as self-renewal and tumor 
initiation. However, little is still known about how thioridazine works, and even whether it 
would affect breast cancer cells at all. Work presented in this thesis shows that high doses of 
thioridazine strongly affect the proliferation and cell viability of all breast cancer cell lines 
tested. However, these effects are independent of DRD2 inhibition. We show that, at lower 
doses, thioridazine can inhibit self-renewal in a DRD2-depedent manner. Interestingly, we 
show that DRD2 promotes self-renewal by activating the STAT3 transcription factor, which 
drives the production of the proinflammatory cytokine IL-6. We further show that the self-
renewal of only the basal-like breast cancer cells is inhibited by thioridazine. Despite these 
interesting findings, there is still much to learn about the effects of thioridazine and the roles 
of DRD2 in breast cancer, and future studies are needed to fully elucidate how thioridazine 
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CHAPTER 1: BACKGROUND AND INTRODUCTION 
 
1.1 Introduction to Breast Cancer and Cancer Stem Cells 
1.1.1 Overview of breast cancer 
 Cancer is the second-leading cause of death in the United States (US), and breast 
cancer is the most common primary tumor site in American women. Breast cancer is also the 
second leading cause of cancer related deaths in women, and it causes about 40,000 deaths 
every year in the US alone (Siegel et al., 2018). For several decades, recommendations for 
routine mammography screenings have been suggesting starting screening at earlier ages, 
and with increased frequencies. These recommendations were implemented to detect more 
early stage breast tumors, before they progress to more dangerous invasive and metastatic 
tumors. Although mammography is highly effective at detecting breast tumors, this increase 
in the detection of early stage tumors has not led to a similar decrease in metastatic disease 
(Kalager et al., 2010). Additionally, because the test is designed to be as sensitive as possible, 
the rate of false positives is alarmingly high, with over 50% of women who have 10 
mammograms having at least one false-positive result (Hubbard et al., 2011). The impact of 
routine mammography has been questioned (Welch et al., 2016), and improvements in the 
technology are being investigated. However, despite increased awareness, screening, and 
targeted therapies metastatic breast cancer remains and important and unsolved problem. 
1.1.2 Breast cancer subtypes 
 The term breast cancer refers to carcinomas derived from the tissues of the mammary 
gland. However, breast cancer is a highly heterogenous disease and perhaps may be more 
precisely considered as a collection of different cancer types that happen to occur in the same 
tissue. These different categorizations of breast cancers are termed subtypes (Perou et al., 




been classified: clinical expression of targetable genes and by gene expression signatures 
that suggest more specific cell types and origins. 
Clinically, breast cancers are classified based on their expression of the estrogen 
receptor (ER), progesterone receptor (PR), or overexpression of the ERBB-family HER2 
receptor. There are effective therapies for hormone receptor positive and HER positive 
tumors, and so the clinical expression of these proteins can dictate the treatment of the 
patient (Figure 1.1) (Brenton et al., 2005; Foulkes et al., 2010). However, about 15% of 
breast cancer patients do not express ER, PR, or the HER2 receptors, and will not benefit from 
the targeted therapies. These tumors are termed triple-negative (Brenton et al., 2005; 
Foulkes et al., 2010). While many triple-negative tumors respond to chemotherapy and are 
treated with surgery, recurrence and distant disease are more common than in non-triple-
negative tumors, especially in the first 3-5 years after treatment (Foulkes et al., 2010; Liedtke 
et al., 2008). Developing effective treatments for patients with triple-negative tumors remains 
an important problem that needs to be addressed. 
 Breast cancers are also classified by molecular subtype, based on gene expression 
signatures. Most breast cancers can be classified as luminal A, luminal B, HER2-enriched, 
basal-like, or claudin-low (Foulkes et al., 2010; Herschkowitz et al., 2007; Perou et al., 2000). 
Many luminal A and B tumors express ER or PR, while a majority of the HER2-enriched tumors 
express high levels of the HER2 receptor (Perou et al., 2000; Weigelt et al., 2009). Strikingly, 
a large majority of basal-like and claudin-low tumors can be clinically classified as triple 
negative and, as would be expected, basal-like and claudin-low tumors have a worse 
prognosis than luminal A tumors (Perou et al., 2000; Sabatier et al., 2014; Sørlie et al., 
2001). It is interesting that the molecular subtypes, developed independent of the 
ER/PR/HER2 status, nonetheless still hold prognostic value (Brenton et al., 2005; Sørlie et 
al., 2001). Since the prognosis for basal-like tumors is poor compared to other subtypes, and 




targeted therapies, new therapies must be implemented to treat these tumors. Work 
presented in this thesis suggests that basal-like breast cancer cells may be more sensitive to 
inhibition of dopamine receptor than the other subtypes. 
1.1.3 Cancer stem cells: origins and relevance in breast cancer 
 Stem cells serve as a reservoir of cellular potential, and they help replenish tissue after 
a wound, or during the normal turnover of cells. Stem cells serve this function with their 
ability to self-renew, or to produce daughter cells that will differentiate, but also daughter 
cells that will remain in the undifferentiated state. Although many different types of stem cells 
are known, the most well-described hierarchy of differentiation is in the hematopoietic 
system, where markers for each stage of differentiation have been established (Zhang et al., 
2018). Importantly, this field established functional assays to characterize hematopoietic 
stem cell activity. The ability of cells to form colonies in colony formation assays or to 
reconstitute all the cell types of the hematopoietic system following transplantation defines a 
hematopoietic stem cell (Boulais and Frenette, 2015; Clevers, 2011; Zhang et al., 2018). It 
was these assays that led to the identification and study of stem-like cancerous cells, termed 
cancer stem cells (CSCs) or tumor initiating cells (TICs) (Figure 1.2). 
 Although many tumors have long been known to be less differentiated than the bulk 
of the tissue of origin, and it had been known since at least 1937 that a single tumor cell could 
transplant and recapitulate a new tumor in a new host (Furth et al., 1937), it was not until 
the 1990s that the cancer stem cell field began to proliferate. Work from the Dick laboratory 
showed that leukemia blasts expressing CD34, but not CD38 (CD34+/CD38-), were the only 
cells that had the ability to form leukemia when engrafted into a new host mouse. This 
discovery led to the assertion that a rare population of CSCs may be responsible for the 
regenerative and metastatic capacity of a tumor (Bonnet and Dick, 1997; Clevers, 2011; 
Lapidot et al., 1994). Since this work was done, the gold standard measure of CSC activity 




assay, although other in vitro methods (colony formation assays, tumorsphere assays, 
organoid formation) have been developed to estimate this activity more quickly and cheaply 
without requiring a large number of mice and months of waiting for tumors to develop. 
Therefore, CSCs are largely defined not just by whether they express certain marker genes 
associated with multipotency, but by their ability to self-renew and initiate a new tumor. 
Further, CSCs are generally more mesenchymal and resistant to radiation and cytotoxic 
therapies (Batlle and Clevers, 2017; Dean et al., 2005; Reya et al., 2001). Therefore, the 
presence of CSCs, which may be difficult to target using conventional therapies, may explain 
why metastases are so difficult to treat, and why certain tumors can recur after what is 
considered a complete clinical response. If most tumors contain CSCs, then those CSCs need 
to be identified, so that therapies can be developed to target them and prevent metastasis 
and recurrence.  
 The discovery of CSCs in human breast cancers initiated a surge of research in the 
CSC field. EpCAM+/CD44+/CD24- human breast cancer cells were shown to be highly 
tumorigenic, with as little as 100 cells initiating a tumor upon transplantation into a mouse 
(Al-Hajj et al., 2003). Despite this intriguing start, there does not seem to be a single 
population of breast CSC markers that can easily distinguish the most tumorigenic cells in 
every breast cancer. Since the landmark discovery by Al-Hajj et al, other non-overlapping 
markers of CSC populations have been found in breast cancers, including ALDH1hi cells 
(Ginestier et al., 2007) and CD133+ cells (Wright et al., 2008). This suggests that there may 
not be a single population of CSCs in breast cancer, but instead heterogenous cell types are 
capable of exhibiting high tumorigenicity and self-renewal.  
As mentioned above, cancer cells that acquire mesenchymal characteristics are 
associated with increased stem-like gene expression patterns as well as increased tumor 
initiation capacity and ability to migrate (Batlle and Clevers, 2017; Guen et al., 2017; Mani 




mesenchymal in nature. However, the first breast CSCs discovered by Al-Hajj et al expressed 
high levels of EpCAM, a cell adhesion molecule highly expressed by epithelial cells. More 
recently, it has been shown that cells that are highly mesenchymal are actually less metastatic 
than cells that show more plasticity and can switch between epithelial and mesenchymal 
states (Celià-Terrassa and Kang, 2018; Celià-Terrassa et al., 2012; Tran et al., 2014). This 
again suggests that most of the current markers used to identify breast CSCs are not 
encompassing the entire heterogeneity of breast CSCs. True breast CSCs may be more 
phenotypically malleable than bulk tumor cells, with ever changing cell surface markers and 
gene expression patterns. Currently, the only concrete method to identifying breast CSCs, is 
to functionally test its ability to form a new tumor. 
1.1.4 Signaling in cancer stem cells 
  Since the discovery of CSCs, many signaling pathways have been shown to regulate 
CSC-like properties like tumor initiation and self-renewal. In breast cancer the most well-
established CSC-promoting pathways are Wnt, Notch, NF-κB, and STAT3. Activation of the 
Wnt pathway has long been associated with stemness and differentiation, and indeed Wnt 
activity has been shown to regulate breast CSCs. Wnt ligands are released from cells, after 
which they can bind to Frizzled receptors at the cell surface, which leads to the stabilization 
of β-catenin. β-catenin can enter the nucleus, where is acts as a potent transcriptional 
activator, and can induce the transcription of many genes that promote survival, proliferation 
and stemness like CyclinD1 and Myc (Clevers, 2006). Overexpression of Wnt-1, one of the 
Wnt ligands, in mice leads to spontaneous tumor formation capable of metastasis (Li et al., 
2000). This suggests that Wnt pathway activation supports the development of tumor and 
metastasis initiating CSCs. Further, Wnt ligands have been shown to promote tumorsphere 
formation in vitro, while Wnt pathway antagonists have been shown to inhibit tumorsphere 
formation (Lamb et al., 2013; Scheel et al., 2011). Further, Wnt pathway activation supports 




 Notch signaling is activated when membrane-associated ligands bind to membrane-
associated Notch receptors on a neighboring cell. This leads to proteolytic cleavage of the 
intracellular domain (ICD) of Notch receptors, after which the ICD can enter the nucleus and 
act as a transcriptional activator (Artavanis-Tsakonas et al., 1999). Activation of Notch 
signaling supports tumorsphere formation and self-renewal in vitro (Dontu et al., 2004). 
Importantly, Notch signaling also supports resistance to anti-estrogen therapies and tumor 
initiation in vivo (Simões et al., 2015). 
 The tumor microenvironment is critical in determining the ultimate fate of a developing 
tumor. Infiltrating immune cells, cancer-associated fibroblasts, and even infiltrating neurons 
have been shown to support tumor growth and metastasis, and prolonged inflammation has 
long been associated with tumor development and metastasis (Grivennikov et al., 2010a; 
Hanahan and Weinberg, 2011; Mantovani et al., 2008). The NF-κB pathway leads to activation 
of a family of transcription factors that strongly regulate inflammatory cytokines, as well as 
genes that promote cell survival and proliferation, and chronic activation of the NF-κB pathway 
is associated with tumorigenesis (Zhang et al., 2017). Inhibition of NF-κB supports 
tumorsphere formation in breast cancer cell lines through the production of inflammatory 
cytokines IL-6 and IL-8 (Kendellen et al., 2014; Lawrence and Baldwin, 2016). Additionally, 
even a transient activation of the NF-κB pathway has been shown to support breast CSCs 
through the production of IL-6 (Iliopoulos et al., 2009). That study also showed that another 
rapidly-inducible transcription factor, STAT3, is activated by IL-6 and drives the CSC 
phenotype (Iliopoulos et al., 2009). 1.3 described in more detail how activated STAT3 is 
associated with poor outcomes and metastasis in breast cancer, and how a STAT3/IL-6 feed-
forward loop supports breast CSCs. 
 Many different pathways have been shown to regulate breast tumorigenesis and the 
CSC phenotype. Importantly, inhibition of a single pathway rarely eliminates tumorsphere 




can exist simultaneously to support different populations of CSCs. There needs to be a 
stronger understanding of the how these pathways support CSCs, how they interact with each 
other, and whether they can be targeted for cancer treatment.  
1.2 Introduction to Dopamine Receptors 
1.2.1 Dopamine Receptors are G-protein-coupled receptors 
 The dopamine receptor family is comprised of 5 G-protein-coupled receptors (GPCRs) 
that are most well characterized for their facilitation of neurotransmission, the communication 
that occurs between firing neurons. Dopamine receptors are activated by the neurotransmitter 
and catecholamine dopamine, which induces intracellular signaling events. Although the 
critical functions of dopamine receptors within the central nervous system have been the focus 
of most of the research on dopamine receptors, there have been numerous dopamine 
receptor-mediated functions discovered in the periphery. Several recent studies have even 
indicated a possible role for dopamine receptors, particularly dopamine receptor 2 (DRD2) in 
promoting cancer cell growth, survival, and the cancer stem cell phenotype. The work 
presented in this thesis focuses on the roles of DRD2 and antipsychotic drugs that target 
dopamine receptors on breast cancer cell growth and self-renewal. 
 Dopamine receptors belong to the GPCR superfamily, which are integral membrane 
proteins characterized by their 7 transmembrane domains and their association with an 
intracellular heterotrimeric complex of G proteins. The three classes of G proteins are 
GDP/GTP-binding Gα subunits (subclassified into Gαi, Gαs, Gαo, Gαq, and Gα12/13), the Gβ, and 
Gγ subunits (Marinissen and Gutkind, 2001). While a receptor is inactive, the αβγ subunits 
are bound together and associated with the receptor, and the Gα subunit is bound to GDP. 
Upon receptor stimulation, the Gα subunit dissociates from the complex, exchanges GDP for 
GTP, and becomes active (Lambright et al., 1996; Marinissen and Gutkind, 2001; Wall et al., 
1995). There are a variety of downstream signaling events mediated by GTP-bound Gα 




al., 2009). The activity of Gα proteins is limited by the rate of GTP hydrolysis. As a 
consequence of GTP hydrolysis to GDP, the protein becomes inactive and reassociates with 
the Gβ/γ subunits and the inactive GPCR. The Gα-mediated GTP hydrolysis can be rapidly 
induced by RGS family kinases (Dohlman and Thorner, 1997). Although signaling downstream 
of GTP-bound Gα proteins are the most well-studied, the Gβ/γ subunits can also mediate 
signaling upon receptor activation. Gβ/γ subunits have been shown to regulate a diverse array 
of effectors including, but not limited to, the activation of calcium and potassium ion channels 
(Ikeda, 1996; Logothetis et al., 1987; Wickman et al., 1994), protein lipase C (PLC) (Boyer 
et al., 1992; Camps et al., 1992), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) 
(Stephens et al., 1994), and the RAS/MEK/ERK pathway (Crespo et al., 1994; Pumiglia et al., 
1995; Smrcka, 2008). 
 There is even greater complexity to GPCR signaling. Upon receptor activation, GRK 
family kinases are activated and phosphorylate intracellular residues on the receptor (Kuehn 
et al., 1973; Moore et al., 2007). These phosphorylation events provide binding sites for β-
arrestins, which bind and inhibit GPCR activation. Further, β-arrestin binding induces clathrin-
mediated internalization, and the receptor can be either recycled back to the plasma 
membrane or trafficked to lysosomes for degradation (Attramadal et al., 1992; Lohse et al., 
1990; Pitcher et al., 1998). Despite the important roles for β-arrestin-mediated GPCR 
inhibition, β-arrestins have been shown to act as scaffold proteins when bound to GPCRs and 
promote the activation of downstream effectors such as Src family kinases (Luttrell et al., 
1999; Shenoy and Lefkowitz, 2011), MAP kinases (DeFea et al., 2000; Luttrell et al., 2001), 
and GSK3β (Povsic et al., 2003), independent of G proteins. Due to the high complexity of 
signaling and many downstream effector pathways, GPCRs are involved in regulating an 
amazingly diverse number of processes including neurotransmission, scent detection, cell 
proliferation, migration, immune cell activation, and more (Rosenbaum et al., 2009). As a 




antagonists available for study and disease treatment (Rosenbaum et al., 2009). Dopamine 
receptors are quite typical GPCRs in this sense with a myriad of neuronal and non-neuronal 
functions, and many small molecules that target each receptor. 
1.2.2 Dopamine receptor genes and structure 
 Although dopamine was discovered in 1957 (Carlsson et al., 1957), and the existence 
of two subclasses of receptors was proposed in 1978 (Spano et al., 1978), the first receptor, 
DRD2, was not cloned until 1988 (Bunzow et al., 1988; Grandy et al., 1989). Since the cloning 
of the dopamine receptors, much has been learned about their gene regulation and structure. 
As mentioned above, the family of 5 dopamine receptors is separated into two subfamilies, 
the D1-like and D2-like receptors. The D1-like receptors are dopamine receptor 1 (DRD1) and 
DRD5, while the D2-like subfamily is comprised of DRD2, DRD3, and DRD4. These two 
subfamilies were first proposed based on whether the receptors were positively coupled to 
adenylate cyclase (AC) and promote the formation of cAMP (the D1-like receptors), or whether 
the receptors were negatively coupled to AC and inhibit cAMP formation (Figure 1.3) (Caron 
et al., 1978; Spano et al., 1978). Although the original distinction between the D1-like and 
D2-like subfamilies was made based on the mode of regulation of AC, many aspects of 
dopamine receptor function and structure are defined by the subfamily distinction. 
 The structure of gene loci differs between the D1-like and D2-like receptors. 
Interestingly, neither of the D1-like receptors contain any introns, while all of the D2-like 
receptors have introns, as well as observed splice variants (Missale et al., 1998). The most 
well-studied dopamine receptor splice variants are the DRD2-long and DRD2-short 
transcripts. The DRD2-short variant does not contain 29 amino acids within the functionally 
important third intracellular loop compared to the DRD2-long isoform. The short and long 
isoforms have been shown to have different expression and effects on neuronal transmission 
(Beaulieu and Gainetdinov, 2011). The DRD2-short isoform is generally expressed 




neurotransmission upon receptor stimulation. However, the DRD2-long isoform is generally 
expressed postsynaptically, and promotes neuronal excitation (Usiello et al., 2000). The D1-
like and D2-like subfamily receptors differ not only in the structure of the gene loci, but also 
in protein structure. 
 Like all GPCRs, dopamine receptors contain 7 transmembrane domains, and the 
proteins start with an extracellular N-terminal domain, then consist of alternating extracellular 
and intracellular loops, and end with a C-terminal intracellular tail. Interestingly, D2-like 
receptors have an extensive third intracellular loop and a short C-terminal tail, which is typical 
of GPCRs that couple to the Gαi family of G proteins. Conversely, D1-like receptors contain a 
short third intracellular loop, but rather a long C-terminal tail, which is indicative of GPCRs 
that couple to the Gαs family of G proteins (Beaulieu and Gainetdinov, 2011; Missale et al., 
1998). These differences explain the original functional distinction between the two 
subfamilies, the opposing regulation of AC and cAMP. Gαi family G proteins generally inhibit 
AC activity, while members of the Gαs family of G proteins activate AC activity. 
 Although the D1-like and D2-like subfamilies have different structures and functions, 
there is evidence that they can signal cooperatively. Activating both DRD1 and DRD2 with 
specific agonists can have different effects than activating either receptor alone. This has been 
shown with dopamine receptor-stimulated arachidonic acid (AA) release. While stimulation 
with a DRD1-specific agonist alone does not affect AA release, stimulation with a DRD2-
specific agonist induced AA release (Piomelli et al., 1991). However, stimulation of both DRD1 
and DRD2 induced an increase on AA over DRD2 stimulation alone (Piomelli et al., 1991). 
There have also been more direct observations of physical associations between DRD1 and 
DRD2. These heteromers have been shown to regulate intracellular calcium and downstream 
gene expression (Hasbi et al., 2009; Lee et al., 2004; Perreault et al., 2014). Interestingly, 
DRD1/DRD2 heteromers were shown to couple to Gαq proteins (Lee et al., 2004), and 




receptor can block heteromer signaling (Hasbi et al., 2009; Verma et al., 2010). Although 
dopamine receptors can easily be classified into two groups based on gene structure and AC 
regulation, dopamine receptor biology is complex, and there are numerous downstream 
signaling pathways regulated by dopamine receptors. 
1.2.3 Dopamine Receptor Signaling 
 Over the past 40 years, there has been extensive research studying the molecular 
mechanisms of dopamine receptor-mediated signaling. As the scope of the work presented in 
this thesis focuses on the roles of DRD2 and antipsychotics that target D2-like receptors, this 
section will also focus mainly on the cellular signaling mediated by DRD2 and the other D2-
like receptors (Figure 1.4). 
 The original distinction of the D2-like receptors is inhibition of AC and a reduction in 
cAMP levels, which results in reduced protein kinase A (PKA) activity (Beaulieu and 
Gainetdinov, 2011; Kebabian and Calne, 1979).  PKA is a multi-subunit serine/threonine 
kinase that is the primary downstream effector of cAMP (Skalhegg and Tasken, 2000). 
Classically, active PKA has been shown to phosphorylate cAMP response element-binding 
protein (CREB), which promotes an association with CREB-binding protein (CBP), which then 
binds to cAMP response elements (CREs) located in gene promoters (Shaywitz and Greenberg, 
1999). Although PKA has been shown to regulate hundreds of targets other than CREB via 
phosphorylation, the most well characterized target downstream of dopamine receptors is 
dopamine and cAMP-regulated phosphoprotein (DARPP-32) (Beaulieu and Gainetdinov, 
2011). DARPP-32 is a regulatory subunit of protein phosphatase 1 (PP1) that, when associated 
with PP1, decreases its phosphatase activity, and activated PKA downstream of D1-like like 
receptors phosphorylates DARPP-32, which increases its association with PP1, decreasing PP1 
activity (Hemmings et al., 1984; Svenningsson et al., 2004). This can amplify PKA-mediated 
dopamine receptor signaling by inhibiting a phosphatase that removes phosphorylation sites 




to a decrease in DARPP-32/PP1 interaction, leading to the dephosphorylation of PKA targets 
(Bateup et al., 2008).  
 Although the most well characterized activity of D2-like receptors is the inhibition of 
AC activity by the activation of Gαi proteins, activation of D2-like receptors also induces 
signaling events mediated by the Gβ/γ subunits. There have been many observed roles for 
Gβ/γ proteins downstream of D2-like receptors, including the regulation of calcium and 
potassium ion channels (Hernández-López et al., 2000; Lavine et al., 2002).  The most well-
studied Gβ/γ-mediated signaling event downstream of D2-like dopamine receptors is the 
activation of phospholipase C (PLC) family enzymes (Hernández-López et al., 2000). Active 
PLC cleaves the phosphatidylinositol head groups from lipids in the plasma membrane, leaving 
diacyl glycerol, which can activate protein kinase C (PKC) signaling, and releasing inositol 
1,4,5-triphosphate (IP3) (Kadamur and Ross, 2013). IP3 induces the release of calcium ions 
from the endoplasmic reticulum, activating further downstream effectors, such as the 
members of the CAM-kinase family (Kadamur and Ross, 2013). The effects of PKC activation 
and cytoplasmic calcium release downstream of PLC activation differ, depending on cell type, 
but downstream of dopamine receptors in neurons, they can have dramatic effects that are 
important in diseases like Huntington’s disease and Alzheimer’s disease (Yang et al., 2016).  
 The G-protein-mediated signaling events discussed above represent only a subset of 
the known mechanisms in which dopamine receptors are known to signal via G-proteins. 
However, dopamine receptors are also known to modulate intracellular signaling via β-
arrestins. As mentioned above β-arrestins were discovered and named for their roles in 
negatively regulating GPCR signaling, but have since been identified as scaffolds that recruit 
other signaling molecules (Luttrell and Lefkowitz, 2002). β-arrestin-mediated signaling has 
much slower kinetics than G-protein-mediated signaling, since β-arrestin binding to the GCPR 
occurs as a feedback mechanism downstream of G-protein activation and occurs from 




arrestin binding to DRD2 can recruit protein kinase B (AKT) and protein phosphatase 2 (PP2). 
While in complex, PP2 dephosphorylates and inactivates AKT (Beaulieu et al., 2005). AKT 
phosphorylates another kinase GSK3β, which inactivates it. Therefore, stimulation of DRD2 
can lead to the activation of GSK3β, which has been shown to be especially important in 
mediating the effects of dopamine receptor stimulation on locomotion and social interaction 
in mice (Beaulieu et al., 2015; Urs et al., 2012). 
 Although the most well-studied signaling mechanisms of dopamine receptors are the 
regulation of cAMP, intracellular Ca2+, ion channels, and serine/threonine phosphorylation, 
dopamine receptors have also been shown to regulate tyrosine kinase cascades. Over 25 
years ago Lajiness et al showed that dopamine can stimulate the tyrosine phosphorylation of 
a number of substrates in DRD2-transfected Chinese hamster ovary cells. Further, they 
showed that DRD2 activity could promote proliferation that was blocked with the broad 
tyrosine kinase inhibitor genistein (Lajiness et al., 1993). Receptor tyrosine kinases (RTKs) 
regulate a large and diverse set of cellular processes, including some that can co-opted by 
cancer cells, such as stemness/self-renewal, cell survival, proliferation, cytokine response and 
production, and cell migration (Schlessinger, 2000). The epidermal growth factor receptor 
(EGFR) is an RTK that has been associated with many pro-tumor functions, and is especially 
active in many triple-negative breast cancers (Nielsen et al., 2004; Reis-Filho and Tutt, 2007). 
Interestingly, DRD2 has been shown to directly promote the transactivation of EGFR, leading 
to AKT and ERK phosphorylation (Swift et al., 2011). DRD2-mediated transactivation of EGFR 
can protect cells against apoptosis in cell line model of rat pheochromocytoma via SRC activity 
(Nair and Sealfon, 2003). Despite this, DRD2 has also been shown to indirectly activate EGFR 
by inducing the release of heparin-bound EGF, through the activation of extracellular 
proteases (Yoon and Baik, 2013), indicating a complex relationship between DRD2 and EGFR 
activation. In addition to EGFR, DRD2 has been shown to transactivate the insulin-like growth 




et al., 2011). Dopamine receptors, including DRD2, have been shown to promote the activity 
of a number of pathways known to promote cancer growth, invasion, or metastasis, yet only 
a small fraction of the research on these receptors, and their agonists and antagonists, has 
been applied to cancer. Most of the research has focused on effects within neurons and 
neuronal function. However, expression of dopamine receptors in non-neuronal cell types has 
been known for many decades, and there is a wealth of research uncovering important roles 
for dopamine receptors in the periphery. 
1.2.4 Peripheral DRD2 
 While the expression of all five dopamine receptors has been observed in peripheral 
tissues, this introduction will focus primarily on the function of D2-like receptors, especially 
with a focus on DRD2. The following reviews extensively cover the functions of all five 
dopamine receptors in the periphery (Beaulieu and Gainetdinov, 2011; Levite, 2016; Missale 
et al., 1998).  
 One of the most well-studied effects of dopamine receptor function outside of neurons 
is the inhibition of prolactin secretion from the pituitary (Figure 1.5). Prolactin is a hormone 
produced and released from the pituitary gland that, among other functions, stimulates 
lactation in mammals (Freeman et al., 2000). Dopamine released from hypothalamic neurons 
stimulate D2-like receptors in the pituitary, which leads to decreased release of prolactin, as 
well as decreased gene transcription (Elsholtz et al., 1991). In fact, hyperprolactinemia, the 
overproduction and release of prolactin, is a common side effect of typical antipsychotics, all 
of which inhibit DRD2 (see below) (Kapur and Seeman, 2001; Missale et al., 1998). Further, 
in patients with prolactin-secreting pituitary tumors, treatment with DRD2 agonists can 
manage prolactin levels (Cunnah and Besser, 1991).  
 Dopamine receptors have other important roles in the endocrine system outside the 
pituitary gland. Dopamine receptors are also expressed in the adrenal glands, where they 




(Missale et al., 1998). Aldosterone is a hormone synthesized in the adrenal glands, but it acts 
in the kidneys to promote water and sodium retention, which increases blood pressure (Lifton 
et al., 2001). Inhibition of D2-like receptors in vivo leads to an increase in aldosterone levels 
(Carey et al., 1979, 1980). Under normal salt and blood pressure conditions, activation of D2-
like receptors does not inhibit aldosterone levels (Carey et al., 1979). This suggests that under 
normal sodium conditions, D2-like receptors maximally inhibit aldosterone secretion. 
Alternatively, when sodium levels are low, renal dopamine secretion is inhibited, which leads 
to decreased dopamine receptor activity, which in turn allow for an increase in aldosterone 
secretion (Chugh et al., 2013). After secretion, aldosterone can make its way to the kidney 
where it promotes water and sodium retention. Interestingly, mice with decreased DRD2 
expression, as well as humans with certain polymorphisms at the DRD2 locus, exhibit 
increased blood pressure (Konkalmatt et al., 2016). This may partly be explained by 
aldosterone regulation, but D2-like receptors also influence blood pressure more directly by 
affecting sodium retention in the kidneys. Dopamine receptors inhibit aldosterone secretion 
from the adrenal gland, which promotes the expression and activity of Na+/K+ pumps in the 
kidney that lead to sodium retention (Salyer et al., 2013). The activity of dopamine receptors 
in the proximal tubule inhibits the activity of the Na+/K+ pumps that lead to sodium retention 
(Bertorello and Aperia, 1990; Carey, 2001). Through these mechanisms, dopamine receptors 
in the periphery are critical to blood pressure homeostasis. 
 Despite the intriguing functions of dopamine and its receptors in several tissues outside 
the CNS, some of the most well-studied functions of peripheral dopamine are in immune cells. 
Not only has the expression of dopamine receptors, to varying degrees, been observed in 
every major immune cell type, but the expression of dopamine synthesis genes and/or 
dopamine transporters have also been observed in many immune cells (Amenta et al., 2001; 




 Dopamine has been shown to support hemapoetic cells by inducing the migration and 
colony-formation activity of hematapoetic stem cells (HSCs) (Spiegel et al., 2007). In 
macrophages, which are myeloid cells that normally phagocytose pathogens and can act as 
antigen presenting cells, DRD2 activity can inhibit TNFα and nitric oxide secretion (Haskó et 
al., 1996). Further, dopamine has been shown to decrease NF-κB DNA binding activity 
(Bergquist et al., 2000). These intriguing observations suggest that DRD2 may subvert 
macrophages away from the inflammatory cytotoxic M1 state, towards a more 
immunosuppressive phenotype. If true, that could indicate that DRD2 activation in tumor 
infiltrating macrophages may support tumor growth and immune avoidance. Interestingly, 
DRD1 and DRD2 have also been shown to facilitate HIV viral entry into macrophage, which is 
mediated by CCR5 (Gaskill et al., 2014). Additionally, DRD2, but not DRD1, can stimulate HIV 
replication within macrophages in an ERK-dependent manner (Gaskill et al., 2009).  
The activity of D2-like receptors has also been shown to influence dendritic cell 
function. Dendritic cells are myeloid cells that primarily act as efficient antigen-presenting 
cells. Antigen presenting cells activate T and B cells by directly binding and exposing the 
foreign antigen on their cell surfaces (Banchereau and Steinman, 1998). Dendritic cells can 
release dopamine while bound to T cells, which supports a Th2 polarization, and if dendritic 
cells are treated with D2-like receptor antagonists, a stronger release of dopamine was 
observed, leading to a higher preference for Th2 polarization (Nakano et al., 2009). By 
activating cytotoxic T cells, Th1 polarized T helper produce a highly inflammatory response 
toward viruses, bacteria, and other single celled pathogens (Abbas et al., 1996). Th2 
responses, on the other hand, are less inflammatory because they release anti-inflammatory 
cytokines like IL-4 and IL-10. Further, by activating eosinophils, Th2 polarized T helper cells 
are important for the response to multicellular pathogens, such as helminths (Abbas et al., 
1996). Interestingly, since cytotoxic T cells are important for immune-mediated tumor cell 




are associated with a tumor permissive microenvironment and metastasis in breast cancer 
(DeNardo et al., 2009; Grivennikov et al., 2010b). 
 In addition to T helper cell polarization, dopamine has generally been shown to inhibit 
the T effector cells. Dopamine, via DRD2 and DRD3 receptors has been shown to inhibit 
proliferation of activated T cells as well as inhibit the production of cytokines in activated T 
cells (Bergquist et al., 1994; Ghosh et al., 2003). Together with the previously discussed 
effects of dopamine on T helper cell and macrophage polarization suggest a possibility that 
dopamine may permit a microenvironment that promotes tumor growth and immune 
evadence. Dopamine, via DRD2 and the other D2-like receptors has been shown to have many 
effects on immune cells. These effects include the activation and polarization of macrophages 
and T cells, which are known to modulate the tumor microenvironment in ways that can 
promote tumor growth or tumor clearance. 
1.2.5 Antipsychotics and Dopamine Receptors in Cancer 
 It has been suggested that all antipsychotics inhibit DRD2, which supports the 
dopamine hypothesis of schizophrenia (Kapur and Seeman, 2000, 2001; Seeman and Kapur, 
2000). This posits that the primary driver of the positive symptoms of schizophrenia are 
caused by an overactive dopaminergic system (Howes and Kapur, 2009). However, many 
antipsychotics also bind to, and act as agonists or antagonists to, many other receptors 
(Besnard et al., 2012; Chibon, 2013; Roth et al., 2004; Vidal and Mestres, 2010). This 
complicates the use of antipsychotics in molecular studies, as it cannot necessarily be 
assumed that inhibition of DRD2 is the mechanism of action.  
The discovery of antipsychotics as anticancer agents is nearly 30 years old, since 
pimozide and thioridazine where shown to reduce the proliferation of breast cancer cells in 
vitro (Strobl and Peterson, 1992; Strobl et al., 1990). Despite this early discovery, the effects 
of DRD2-targeting antipsychotics went largely unexplored for several decades. A small 




transformed stem cells, but not normal stem cells, identified the DRD2-targeting antipsychotic 
thioridazine as a lead candidate (Sachlos et al., 2012). Since then, a rush of papers has been 
published demonstrating thioridazine, or other antipsychotics such as haloperidol, could target 
cancer stem cells, induce apoptosis, and block proliferation in many cancer cell types including 
breast, lung, ovarian, brain, and colon (Caragher et al., 2019; Cheng et al., 2015; 
Johannessen et al., 2018; Li et al., 2014; Liu et al., 2018; Luo et al., 2016; Meng et al., 2016; 
Wei et al., 2006; Yin et al., 2015; Yong et al., 2017; Yue et al., 2016; Zhang et al., 2016; 
Zong et al., 2014). Most of these studies use high concentrations of thioridazine (10-20µM) 
and observe strong effects on apoptosis induction and reduced viability. Since antipsychotics, 
especially thioridazine bind numerous receptors tightly, some with a Ki of less than 10nM 
(Besnard et al., 2012), it remains unclear how these agents are having such strong effects, 
and even whether inhibition of DRD2 is required. Not only are the mechanisms of the effects 
of antipsychotics on cancer cells unknown, but so are the cell types that are most sensitive 
and most resistant. To this point, no studies have indicated whether there are certain cell 
lines that are more or less sensitive to thioridazine. If thioridazine, or any other antipsychotic, 
will be used in the treatment of cancers, it must be known which patients will benefit the most 
from such a treatment.  
The work presented in this thesis attempts to address these issues. First, we searched 
for the mechanisms of the effects of thioridazine on breast cancer cells, including the roles of 
DRD2. Then, we approached the important question of which tumor cells are the most 
sensitive to thioridazine. 
1.3 Introduction to JAK/STAT Pathway 
1.3.1 Overview of the JAK/STAT Pathway 
 The JAK/STAT pathway turns signals from cytokines binding to plasma membrane 
receptors into changes in gene expression. There are 4 non-receptor tyrosine kinases (TYK2, 




Activated JAK-family kinases can phosphorylate tyrosine residue on STAT-family transcription 
factors (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). The STAT-family 
transcription factors are normally kept in the cytosol in an inactive state, but upon 
phosphorylation by JAKs, dimerize and translocate to the nucleus, where they activate 
transcription (Schindler et al., 2007; Stark and Darnell, 2012). The activation of the STAT-
family transcription factors is critical for the innate immune response, the adaptive immune 
response, autoimmunity, and even embryonic stem cell pluripotency (Forbes et al., 2016; Raz 
et al., 1999; Schindler et al., 2007; Stark and Darnell, 2012). Although all STAT-family 
transcription factors are vital for the proper mammalian development and immune responses, 
activation of STAT3 has been particularly well documented to be pro-tumorigenic (Banerjee 
and Resat, 2016; Yu et al., 2014). 
1.3.2 Activation of STAT3 in cancer 
Strong, but transient activation of STAT3 can be vital to appropriate cellular responses 
to pathogens. However, persistent or chronic activation of STAT3 promotes tumorigenesis by 
regulating gene expression to promote cell survival, proliferation, migration (EMT), drug 
resistance, and CSC-like character (Figure 1.7) (Gao et al., 2007; Iliopoulos et al., 2009; 
Korkaya et al., 2012; Lee et al., 2010; Levy and Darnell, 2002; Oh et al., 2013; Sonnenblick 
et al., 2015; Yu et al., 2014). One of the most well-established mechanisms of persistent 
STAT3 activation is via the IL-6/STAT3 feed forward loop. Interleukin-6 (IL-6) is a cytokine 
that, when bound to its receptor in complex with the tyrosine kinase GP130, can activate JAK-
family kinases, leading to STAT3 activation. Interestingly, IL-6 is also a STAT3 target gene. 
Activation of STAT3 by IL-6 can induce more IL-6 production, thereby leading to further 
induction of STAT3 activity and establishing persistent STAT3 activation (Yu et al., 2014). This 
chronic activation of STAT3 can promote CSC-like activities in breast cancer like drug 
resistance and metastasis (Dethlefsen et al., 2013; Iliopoulos et al., 2009; Korkaya et al., 




breast cancer, and despite anti-IL6 therapies that already treat immune disorders, the 
translation to cancer therapeutics has been slow (Hunter and Jones, 2015). Developing 
therapies that inhibit the chronic activation of the IL-6/STAT3 feed-forward loop can be critical 
to reducing dangerous breast cancer complications such as drug resistance, recurrence, or 
metastasis. 
1.4 – Conclusions and views 
 The most dangerous events in the progression of breast cancer are drug resistance, 
recurrence, and metastasis. CSCs are hypothesized to drive these events in many tumor 
types, including breast cancers. Additionally, the IL-6/STAT3 feed-forward loop can support 
CSCs and their pro-tumorigenic behaviors. The work presented in chapter 2 shows that DRD2 
can, in some triple-negative breast cancer cells, promote self-renewal via STAT3/IL-6.  
Importantly, we show that thioridazine, a cheap FDA-approved DRD2 antagonist, can inhibit 
STAT3 activation, IL-6 production, and tumorsphere initiation in some triple-negative breast 
cancer cells. In chapter 3, we show that the self-renewal of basal-like breast cancer cell lines 
is the most sensitive to thioridazine and DRD2-inhibition. Additionally, we provide preliminary 
evidence that the plasminogen pathway can enhance DRD2-promoted self-renewal.  This 






Figure 1.1 – The clinical subtypes of breast cancer. The expression or lack of 


























Figure 1.2 – Experiments that measure tumor initiation activity within a 
population of cells. In all tumor initiation experiments, the rate of tumor or colony 
initiation is tested in a population of dissociated single cells. The in vitro tumorsphere assay 
and colony formation assay can quickly estimate the tumor initiation activity of a population 
of cells. The gold standard assay is the in vivo transplantation assay, in which the tumor 


















Figure 1.3 – D1-like vs. D2-like dopamine receptors. There are two subfamilies of 
dopamine receptors. The D1-like family receptors couple to Gαs, contain no introns, and 
have a long C-terminal tail. The D2-like receptors couple to Gαi, contain introns and have 















Figure 1.4 – The main downstream mediators of DRD2 signaling. DRD2, like many 
GPCRs, has been shown to signaling through numerous downstream pathways. The most 





















Figure 1.5 – DRD2 regulation of prolactin release. Dopamine released from 
hypothalamic neurons activates DRD2 in pituitary cells, which inhibits prolactin secretion. 






Figure 1.6 – Dopamine receptors in the adrenal glands decrease blood pressure by 
inhibiting aldosterone release. When sodium levels are low, dopamine release from renal 
cells is inhibited. This decreases dopamine receptor activation in nearby adrenal cells. 
Adrenal dopamine receptors inhibit aldosterone release, and when low sodium limits 
dopamine release, aldosterone is release to the renal cells, where it promotes sodium 
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CHAPTER 2: THIORIDAZINE INHIBITS SELF-RENEWAL IN BREAST CANCER CELLS 
VIA DRD2-DEPENDENT STAT3 INHIBITION, BUT INDUCES A G1 ARREST 
INDEPENDENT OF DRD2 
2.1 - Introduction 
The family of dopamine receptors consists of 5 G-protein-coupled receptors (GPCRs). 
There are two subfamilies of dopamine receptors, which couple to different G-proteins and 
can have different effects on signaling. The Gαs-coupled D1-like receptors (DRD1 and DRD5) 
induce cAMP production, whereas the Gαi/o-coupled D2-like receptors (DRD2, DRD3, and 
DRD4) inhibit cAMP production (Beaulieu and Gainetdinov, 2011; Missale et al., 1998). DRD2 
in particular has been extensively studied due to its disease relevance. Excess or reduced 
DRD2 activity is thought to be responsible for diseases such as schizophrenia and Parkinson’s 
disease, and compounds that preferentially inhibit or activate DRD2, respectively, can be used 
to manage these diseases (Iversen and Iversen, 2007; Missale et al., 1998). Although much 
of the research on dopamine receptors has focused on neurons, functions for dopamine and 
its receptors outside of the CNS have been reported. Expression of dopamine receptors has 
been observed in renal cells, where they regulate inflammation and blood pressure 
(Konkalmatt et al., 2016; Missale et al., 1998; Zhang et al., 2012). Dopamine receptors, 
including DRD2, have also been identified in immune cells. The effects of dopamine and its 
receptors have been especially well studied in T-cells, where they regulate T-cell activation 
and proliferation (Basu et al., 2010; Levite, 2016; Mei et al., 2012). 
 Recently, evidence has emerged that DRD2-targeting antipsychotics can block the 
growth of several cancer types, including leukemia, glioblastoma, colorectal, lung, and breast 




Yue et al., 2016; Zhang et al., 2016). Interestingly, the DRD2-targeting antipsychotic 
thioridazine had been shown as early as 1992 to inhibit breast cancer cell growth (Strobl and 
Peterson, 1992). Further, high expression of DRD2 mRNA has been observed in glioblastoma 
and pancreatic cancer (Jandaghi et al., 2016; Li et al., 2014). DRD2-targeting antipsychotics 
such as thioridazine and haloperidol have been reported to induce apoptosis and reduce self-
renewal in cancer cells (Cheng et al., 2015; Li et al., 2014; Sachlos et al., 2012; Yue et al., 
2016; Zhang et al., 2016). Despite these discoveries, the molecular mechanisms by which 
antipsychotics such as thioridazine lead to reduced cancer cell growth and survival are still 
unclear. Several studies of the effects of thioridazine have been performed using high 
concentrations (10-20µM) of drug (Cheng et al., 2015; Sachlos et al., 2012; Yue et al., 2016; 
Zhang et al., 2016). It remains unclear whether certain cell types may be more or less 
sensitive to treatment with antipsychotics, whether thioridazine can inhibit self-renewal 
effects independent of cell toxicity, and whether these effects are mediated by inhibition of 
DRD2 as is generally assumed. However, it is clear that DRD2-targeting antipsychotic 
compounds have very strong effects on many cell types. 
 STAT3 is an inducible transcription factor that has been shown to promote 
proliferation, prevent apoptosis, and affect cellular differentiation (Yu et al., 2014). STAT3 is 
one of 6 STAT family transcription factors that are primarily known for roles in pathogen 
response and inflammation (Stark and Darnell, 2012). Not only has STAT3 been shown to 
promote self-renewal in cancer stem cells and normal embryonic stem cells, but its activation 
also increases breast cancer proliferation and invasion (Banerjee and Resat, 2016; Marotta et 
al., 2011; Matsuda et al., 1999; Staniszewska et al., 2012; Wei et al., 2014). A number of 
stimuli are capable of activating STAT3, including the widely-studied cytokine interleukin-6 
(IL-6). IL-6 forms a complex with IL-6 receptor and GP130 and activates the tyrosine kinase 
activity of GP130. Active GP130 can phosphorylate and activate members of the JAK tyrosine 




Importantly, IL-6 is also a target gene of STAT3, and a feed-forward loop can be established 
that leads to chronically activated STAT3. Studies indicate that chronically activated 
STAT3/IL-6 promotes more aggressive and drug resistant breast cancers (Korkaya et al., 
2012; Real et al., 2002; Sonnenblick et al., 2015). Although receptor tyrosine kinase signaling 
is a well-studied mode of STAT3 activation, GPCRs such as S1P1R have been shown to 
promote STAT3 activation by directly binding to JAKs (Lee et al., 2010). Intriguingly, D2-like 
receptors have been shown to promote proliferation by activating tyrosine kinase activity 
(Lajiness et al., 1993; Luo et al., 1999). This suggests a possible connection between 
JAK/STAT/IL-6 and the effects of DRD2-targeting antipsychotics on cancer cells. 
While high STAT3 activity is associated with more aggressive cancers, triple-negative 
breast cancers (TNBCs) in particular are associated with high STAT3 activity (Banerjee and 
Resat, 2016; Wei et al., 2014). Previous work from our lab has also shown that IL-6 is a 
critical factor for the maintenance of tumor initiating cells in triple-negative breast cancer cell 
lines (TNBCLs) (Kendellen et al., 2014). Triple-negative breast cancer is a subtype of breast 
cancer that lacks the expression of the HER2, estrogen, and progesterone receptors. 
Consequently, there are no targeted therapies for TNBC, which has a poor prognosis 
compared to other breast cancer subtypes (Bianchini et al., 2016).  
In this study, we show that the DRD2-targeting drug thioridazine inhibits the self-
renewal of some TNBCLs, but not others. At higher concentrations, thioridazine can induce a 
G1 arrest and block cell viability in all tested TNBCLs. We demonstrate that the inhibition of 
self-renewal is dependent on DRD2 and activated STAT3. However, the strong reduction in 
cell viability is not only independent of STAT3 activity, but also independent of DRD2.  
2.2 - Results 





Thioridazine, a DRD2 inhibitor, has been reported to decrease cancer cell proliferation 
and stemness in leukemia, glioblastoma, colorectal, lung, and breast cancer cell lines (Cheng 
et al., 2015; Sachlos et al., 2012; Strobl and Peterson, 1992; Yin et al., 2015; Yue et al., 
2016; Zhang et al., 2016). DRD2 mRNA expression across different breast cancer subtypes 
was assessed using TCGA data. Interestingly, basal-like, claudin-low, and lobular tumors had 
highest expression of DRD2 compared to other breast cancer subtypes (Figure 2.1). Since 
basal-like and claudin-low tumors are predominantly triple-negative, the effects of 
thioridazine were assessed on a panel of triple-negative cell lines (Perou, 2010). Although 
high expression was also observed in lobular breast cancer, our group has previously studied 
the self-renewal of triple-negative breast cancers (Kendellen et al., 2014), so we studied the 
effects of DRD2-targeted antipsychotics in triple-negative breast cancer cell lines (TNBCLs). 
To test whether thioridazine has effects on the self-renewal of TNBCLs, the in vitro 
tumorsphere assay was used. Six triple-negative cell lines were treated with DMSO, 1µM, 
2µM, or 5µM thioridazine once and were cultured for seven days before the number of spheres 
were counted. Interestingly, some TNBCLs (SUM149, HCC1143, HCC1937) were found to be 
sensitive where thioridazine caused a dose-dependent decrease in tumorsphere number; 
whereas others (SUM159, MDA-MB-231, HCC38) were resistant, showing no significant 
decrease in tumorsphere numbers at these concentrations of thioridazine (Figure 2.2A). To 
more strigently test whether thioridazine inhibits self-renewal, secondary tumorsphere 
formation of SUM149 and SUM159 cells was tested in the presence of thioridazine. Indeed, 
thioridazine treatment inhibits secondary tumorsphere formation of SUM149 cells, but not of 
SUM159 cells (Figure 2.2B). Since thioridazine is an inhibitor of DRD2, the observed 
differences in sensitivity were predicted to arise from expression of DRD2. Although HCC1143 
cells have abundant expression of DRD2 compared to the other TNBCLs, DRD2 mRNA 
expression did not correlate with whether thioridazine will inhibited sphere formation (Figure 




because DRD2 is more highly expressed in the sphere-forming cells in the SUM149 cell line. 
To test this, DRD2 mRNA expression was measured in tumorspheres relative to adherently 
grown SUM149 and SUM159 cells. Indeed, DRD2 is expressed more highly in SUM149 
tumorspheres than in adherently grown cells (Figure 2.3). However, it is also expressed more 
highly in SUM159 tumorspheres than in adherently grown cells (Figure 2.3). This suggests 
that the lack of response in SUM159 tumorspheres is not due to low or absent expression of 
the receptor. Unfortunately, we were unable to specifically detect DRD2 protein by western 
blot. Antibodies against dopamine receptors, as is the case with many other GPCRs, are 
notoriously nonspecific (Bodei et al., 2009; Stojanovic et al., 2017). 
A decrease in tumorsphere formation may be caused by inhibited self-renewal, or 
indirectly via reduced cell proliferation or increased death. In this regard, thioridazine has 
been reported to decrease cell viability in a number of cancer cells (Cheng et al., 2015; 
Sachlos et al., 2012; Yue et al., 2016; Zhang et al., 2016). To test the effects of thioridazine 
on adherently grown TNBCLs, cell viability was measured by detecting ATP abundance after 
72 hours of thioridazine treatment. In agreement with studies on other cancer cell lines, 
thioridazine dramatically reduced cell viability in TNBCLs at higher doses (Figure 2.2D). 
Interestingly, there is only a 3-fold range in the IC50 of thioridazine across all 6 TNBCLs tested 
(Table 2.1). We confirmed these results on SUM149 and SUM159 cells by counting cell number 
after 72 hours of thioridazine exposure. Both the SUM149 cells and the SUM159 cells show 
reduced cell numbers when treated with 2µM or 5µM, but not 1µM thioridazine (Figure 2.2E 
and F). Fewer SUM149 cells are counted after 2-4 day of 5µM thioridazine (Figure 2.2E). On 
the other hand, there are SUM159 cells still growing when treated with 5µM thioridazine 
(Figure 2.2F). It is interesting to note that 1µM thioridazine inhibits tumorsphere formation in 
SUM149 cells, even though cell viability is unaffected. This suggests that at 1µM thioridazine 
has a specific effect on self-renewal in this cell line. On the other hand, doses as high as 5µM 




completely, inhibit proliferation. This suggests that thioridazine preferentially targets non-
sphere-forming cells in this cell line. 
To determine if thioridazine leads to induction of apoptosis, the proportion of sub-G1 
cells was analyzed in response to thioridazine treatment. 5µM thioridazine treatment modestly 
increased the proportion of sub-G1 SUM149 cells (Figure 2.4A). Accordingly, a slight induction 
of caspase 3/7 activity and PARP-1 cleavage was observed (Figure 2.4B and C). These data 
indicate that while apoptosis increases modestly upon 5µM thioridazine treatment, the loss in 
cell viability is primarily non-apoptotic at this concentration. ONC201 is a novel compound 
known to strongly induce apoptosis in many different cancer cell types including colorectal, 
AML, and breast cancer cells (Edwards and Ge, 2018; Greer et al., 2018; Prabhu et al., 2015). 
It is also a DRD2 antagonist, like thioridazine (Madhukar et al., 2017). It was originally 
discovered for its ability to induce apoptosis by inducing TNF-related apoptosis inducing ligand 
(TRAIL). ONC201 treatment inhibits AKT, which releases Foxo3a to the nucleus, and Foxo3a 
induces the transcription of TRAIL (Prabhu et al., 2015). We tested whether thioridazine may 
work via this mechanism. While thioridazine does dose-dependently inhibit AKT (Figure 2.5A), 
an increase in nuclear Foxo3a is not observed, nor is there a significant increase in TRAIL 
production (Figure 2.5B and C). Therefore, while thioridazine does inhibit AKT, like ONC201, 
it does not induce Foxo3a/TRAIL-mediated apoptosis. 
2.2.2 Thioridazine induces cell-cycle arrest 
To address whether thioridazine causes a cell-cycle defect, the cell-cycle distribution 
of SUM149 cells was assessed by flow cytometry after propidium iodide staining in cells that 
were treated with increasing doses of thioridazine for 48 hours. An increase in the proportion 
of G0/G1 cells was observed when SUM149 cells were treated with 5µM thioridazine (Figure 
2.6A and B). Changes in proteins involved in S-phase entry were assessed by western blot in 
response to thioridazine treatment. Interestingly, an increase in the CDK inhibitor 




was observed in as little as one hour (Figure 2.6C). These data indicate that 5µM thioridazine 
treatment blocks the G1-S phase transition, leading to a cell cycle-arrest. 
2.2.3 Thioridazine inhibits STAT3 activity 
IL-6 is a pro-inflammatory cytokine known to promote tumor growth (Dethlefsen et 
al., 2013; Grivennikov et al., 2009; Kumari et al., 2016; Oh et al., 2013). Previous work from 
our group showed that IL-6 promotes tumor imitating cells in TNBCLs (Kendellen et al., 2014), 
and it has been shown to be a part of an IL-6/STAT3 feed-forward loop that promotes 
resistance to trastuzumab in Her2+ breast cancer cells (Korkaya et al., 2012). We first 
measured IL-6 mRNA abundance in all 6 TNBCLs used in the tumorsphere assay. 
Interestingly, cell lines that were sensitive to thioridazine in the tumorsphere assay expressed 
more IL-6 mRNA (Figure 2.7A). To test whether thioridazine treatment affects IL-6 expression 
SUM149 cells were treated with thioridazine for 1 – 8 hours, total RNA was isolated and IL-6 
mRNA abundance was measured by qPCR. Thioridazine induced a rapid decrease in IL-6 
transcript abundance, and that suppression was sustained for at least 8 hours (Figure 2.7B). 
Secreted IL-6 protein was measured by ELISA 4 hours after treatment with thioridazine. A 
dose-dependent decrease of soluble IL-6 in the medium was observed (Figure 2.7C). IL-6 is 
a target gene of the STAT3 pathway and can also form a feed-forward loop by activating 
STAT3. For these reasons we investigated whether thioridazine treatment can inhibit STAT3 
activation. To do this, we measured phosphorylation of STAT3 at Y705, which is important for 
STAT3 dimerization and transcriptional activity (Hunter and Jones, 2015). Thioridazine 
treatment caused a dose-dependent decrease in the phosphorylation of STAT3 at Y705 in 
SUM149 cells, but not SUM159 cells (Figure 2.7D). Inactive STAT3 is normally excluded from 
the nucleus, but translocates to the nucleus upon pathway activation. We tested whether 
SUM149 cells have nuclear STAT3, and whether thioridazine causes a reduction. Indeed, total 




and F). Together, these data show that thioridazine inhibits STAT3 activation and downstream 
IL-6 transcription in SUM149 cells. 
2.2.4 Thioridazine requires STAT3 to inhibit self-renewal, but not proliferation or survival 
Having shown that thioridazine inhibits STAT3, we tested whether STAT3 is required 
for the ability of thioridazine to inhibit self-renewal and proliferation of SUM149 cells. First, 
we tested whether STAT3 is required for thioridazine-mediated inhibition of self-renewal. To 
do this, SUM149 cells were transfected with siControl or siSTAT3. Then they were cultured in 
a tumorsphere assay and treated with DMSO or 1µM thioridazine and the number of spheres 
formed were counted after one week. As expected from previous results, thioridazine caused 
a reduction in sphere formation (Figure 2.8A). Knockdown of STAT3 also reduced tumorsphere 
formation, consistent with its reported role in maintaining cancer cell self-renewal (Figure 
2.8A). Interestingly, 1µM thioridazine did not cause an additional decrease in sphere 
formation in the siSTAT3-treated SUM149 cells (Figure 2.8 This suggests that thioridazine 
inhibits self-renewal in these cells by inhibiting STAT3 activity. Since thioridazine reduces IL-
6 production, which itself also promotes STAT3 activation, we tested whether addition of 
recombinant IL-6 (rIL-6) could rescue tumorsphere formation. Indeed, rIL-6 treatment 
increased tumorsphere number in DMSO-treated SUM149 cells as well as it does in 
thioridazine-treated SUM149 cells (Figure 2.8B). To confirm that IL-6 inhibition is downstream 
of thioridazine, we tested if rIL-6 treatment can induce pY705-STAT3 in the presence of 
thioridazine. Indeed, rIL-6 induced pY705-STAT3 in control treated SUM149 cells and in 
thioridazine treated SUM149 cells (Figure 2.8C). Thioridazine also caused a reduction in cell 
viability at high concentrations. To test whether STAT3 inhibition is also required for 
thioridazine-induced inhibition of proliferation and cell viability, siControl and siSTAT3 treated 
SUM149 cells were treated with 1µM, 2µM, or 5µM thioridazine, and cultured adherently for 
72 hours before the number of remaining cells were counted. Interestingly, siSTAT3 treatment 




similarly in siControl- and siSTAT3-treated cells (Figure 2.8D). These data demonstrate that 
while thioridazine inhibits self-renewal in SUM149 cells via STAT3 inhibition, the proliferation 
and cell viability defects are not mediated by STAT3 inhibition. 
2.2.5 DRD2 promotes sphere formation in SUM149 cells 
 To test unique functions for DRD2 in TNBCLs, we first measured tumorsphere 
formation in SUM149 and SUM159 cells treated with siControl or siDRD2. Interestingly, 
siDRD2 treatment reduced tumorsphere formation in SUM149 cells, but not in SUM159 cells 
(Figure 2.9A and B), consistent with the effects of thioridazine on tumorsphere number in 
these cells. The magnitude of DRD2 knockdown was confirmed by qPCR (Figure 2.10). To 
confirm that this decrease in sphere formation was not due to an offtarget effect of the siRNA, 
SUM149 cell lines stably expressing shRNA targeting DRD2 were generated, and DRD2 
knockdown was confirmed by qPCR (Figure 2.10). Again, knockdown of DRD2 decreased 
tumorsphere formation in SUM149 cells (Figure 2.9C). To further confirm the specificity of 
knockdown results, DRD2-CRISPR cells were generated and tumorsphere formation was 
determined. A decrease in DRD2 mRNA was observed in DRD2-CRISPR cells (Figure 2.10), 
and presence of mutations at the cut site were also confirmed (Figure 2.11). Indeed, the 
CRISPR-DRD2 cells also formed fewer tumorspheres than control cells (Figure 2.9D). In order 
to more stringently test whether DRD2 promotes self-renewal in SUM149 cells, DRD2-CRISPR 
spheres were dissociated and cultured again as secondary tumorspheres. Again, a decrease 
in tumorsphere formation was observed, although more modest than primary tumorsphere 
formation (Figure 2.9E). We tested whether chlorpromazine, an antipsychotic similar in 
structure to thioridazine and a known DRD2 antagonist, could also suppress sphere formation. 
Indeed, chlorpromazine treatment inhibited sphere formation in a dose-dependent manner 
(Figure 2.9F). To further test if DRD2 promotes self-renewal in SUM149 cells, a highly specific 
DRD2 inhibitor amisulpride was used (Besnard et al., 2012). Treatment with as little as 500nM 




cells (Figure 2.9G). Interestingly, the reduction in tumorsphere formation induced by 1µM 
amisulpride is similar to that induced by 1µM thioridazine or chlorpromazine. This suggests 
that specifically targeting DRD2 affects self-renewal, but not proliferation (see below, see 
discussion). Tumorsphere formation in response to a well-characterized DRD2/3 specific 
agonist quinpirole was also tested, which caused an increase in tumorsphere formation (Figure 
2.9H). These data confirm that DRD2 promotes self-renewal in the SUM149 cell line. 
2.2.6 DRD2 promotes STAT3 activation 
Since DRD2 promotes tumorsphere formation in SUM149 cells, and thioridazine 
inhibits tumorsphere formation via STAT3 inhibition, we tested whether DRD2 itself regulates 
STAT3 activation. To do this we first used the DRD2 antagonist chlorpromazine and observed 
its effect on STAT3 phosphorylation in SUM149 cells. Indeed, chlorpromazine decreased 
pY705-STAT3 (Figure 2.12A). Additionally, amisulpride, the highly specific DRD2/3 inhibitor 
also decreased pY705-STAT3 (Figure 2.12B). We were unable to observe decreased pY705-
STAT3 when DRD2 was knocked down with siRNA or shRNA (Figure 2.13). This may be due 
to compensatory mechanisms of STAT3 activation that arise within the hours or days after 
knockdown. To directly test if DRD2 can promote STAT3 activation, we overexpressed DRD2 
in SUM159 cells. As shown earlier, thioridazine does not decrease pY705-STAT3 in these cells 
(Figure 2.7D). Interestingly, DRD2 overexpression increased pY705-STAT3 in SUM159 cells 
(Figure 2.12C), and most importantly, the increase in pY705-STAT3 was sensitive to 
thioridazine treatment (Figure 2.12C). Since 1µM thioridazine reduces tumorsphere formation 
via STAT3 in SUM149 cells, but very little pY705-STAT3 decrease is observed when SUM149 
cells are treated with 1µM thioridazine (Figure 2.7D), we tested whether 1µM thioridazine 
could reduce pY705-STAT3 in SUM149 cells cultured as spheres. Indeed, a decrease in pY705-
STAT3 was observed in SUM149 spheres treated with 1µM thioridazine (Figure 2.12D). 
Further, we show that similar to thioridazine treatment, rIL-6 treatment rescued tumorsphere 




shDRD2 cells, rIL-6 increased pY705-STAT3 (Figure 2.14). This result shows that DRD2 is not 
required for the effects of IL-6, and that IL-6 is downstream of DRD2/STAT3 in these cells. 
These data confirm that DRD2 can promote STAT3 activity in SUM149 cells, and that 
thioridazine targets DRD2 to inhibit STAT3 activity. 
2.2.7 Thioridazine inhibits self-renewal, but not cell viability via DRD2 inhibition 
It is still unknown whether thioridazine reduces self-renewal and cell proliferation by 
inhibiting DRD2, or if those functions result from its activities on other receptors. To test 
whether the self-renewal inhibition by thioridazine results from DRD2 inhibition, the 
tumorsphere assay was used. SUM149 cells treated with siControl or siDRD2 were also treated 
with DMSO or 1µM thioridazine. As expected, both siDRD2 and thioridazine treatment alone 
caused a reduction in tumorsphere formation. However, thioridazine treatment had no effect 
on sphere formation in siDRD2 cells (Figure 2.15A). This suggests that DRD2 is required for 
thioridazine to inhibit tumorsphere formation. To confirm this, the same experiment was 
repeated, but with DRD2-CRISPR SUM149 cells. And indeed, while 1µM thioridazine decreased 
tumorsphere formation in control cells, it had no effect on DRD2-CRISPR cells (Figure 2.15B). 
Since the ability of thioridazine to inhibit self-renewal is dependent on DRD2, we tested 
whether the inhibition of proliferation by thioridazine is also a dependent on DRD2. To do this, 
we first observed the growth of SUM149 DRD2-CRISPR cells by counting the number of cells 
72 hours after seeding. Interestingly, a decrease in cell number in DRD2-CRISPR cells was 
not observed (Figure 2.15C). We also counted cell numbers after treatment with the DRD2 
specific inhibitor amisulpride, and no proliferation inhibition was detected at any dose tested 
(Figure 2.15D). This indicates that DRD2 does not support cell proliferation in SUM149 cells. 
Additionally, we measured whether DRD2 is required for thioridazine to inhibit proliferation in 
SUM149 cells. To do this, control or DRD2-CRISPR cells were treated with DMSO or 
thioridazine for 72 hours and then cells were counted. Thioridazine induced the same dose-




These data show that while thioridazine inhibits sphere formation and self-renewal via DRD2 
inhibition, it inhibits proliferation and cell viability by a different mechanism. 
2.3 - Discussion 
Antipsychotics that target DRD2 have been shown to inhibit proliferation and self-
renewal as well as induce apoptosis in leukemia, lung, colon, and brain cancer cells (Cheng 
et al., 2015; Li et al., 2014; Sachlos et al., 2012; Yue et al., 2016; Zhang et al., 2016). The 
effects of these compounds are generally assumed to be mediated by DRD2 inhibition. 
Notably, these studies only report strong effects when thioridazine is used at 10-20µM (Cheng 
et al., 2015; Sachlos et al., 2012; Yue et al., 2016; Zhang et al., 2016). At these 
concentrations, thioridazine may have effects not mediated by DRD2 inhibition, and 
determining which effects of antipsychotic treatment are DRD2-dependent or independent is 
an important distinction to make in order to further identify drug targets in cancer. In addition, 
the mechanisms that mediate the antitumor effects of these compounds remain largely 
unknown.  
In this study, we demonstrate that thioridazine blocks the self-renewal of several 
TNBCLs, while the self-renewal of other TNBCLs is unaffected (Figure 2.2B). Importantly, we 
show that thioridazine inhibits self-renewal via DRD2 (Figure 2.15). Additionally, we 
demonstrate that additional DRD2-targeting antipsychotics also inhibit self-renewal (Figure 
2.9). We also show that thioridazine induces a G1 arrest and dramatically decreases 
proliferation (Figure 2.2 and 2.6). These proliferation effects of thioridazine are not dependent 
on DRD2 (Figure 2.15). Further, we demonstrate that DRD2 promotes self-renewal by 
regulating STAT3/IL-6 activity in SUM149 cells. STAT3, similar to DRD2, does not support 
proliferation and cell viability, but instead primarily supports self-renewal (Figure 2.8). Based 
on these data, we developed a model where DRD2 supports STAT3 activation to maintain a 




Regarding the effects of thioridazine on self-renewal, we show that concentrations as 
low as 1µM thioridazine are capable of decreasing tumorsphere formation in SUM149 cells 
(Figure 2.2B), and that proliferation and cell viability are unaffected at those doses (Figure 
2.2E and F). This suggests that effects on self-renewal are not confounded by effects on cell 
viability at that dose. Furthermore, the DRD2/3 specific antagonist amisulpride blocks sphere 
formation to a similar degree as 1µM thioridazine (Figure 2.9G and 2.2B), even though it does 
not inhibit proliferation (Figure 2.15D). This further supports that DRD2 promotes self-
renewal in SUM149 cells, but the proliferation inhibition is DRD2-independent. In contrast, in 
SUM159 cells doses of thioridazine as high as 5µM do not affect tumorsphere formation 
(Figure 2.2B), although cell viability is dramatically decreased (Figure 2.2E and G). This 
indicates that while thioridazine can reduce the proliferation and viability of the bulk of 
SUM159 cells, it is unable to inhibit the activity of sphere-forming cells at these 
concentrations. Together, our data show that in certain cells (SUM149) DRD2 supports 
sphere-forming cells, and that this activity can be targeted with thioridazine, when used at 
1µM. As increasing doses of thioridazine are used (5µM), a G1 arrest and loss of cell viability 
independent of DRD2 activity occurs. In other cells (SUM159), thioridazine cannot inhibit self-
renewal via DRD2/STAT3 in sphere-forming cells. However, thioridazine can still inhibit the 
proliferation of the bulk of cells at 5µM, but the sphere-forming cells are more resistant than 
the bulk of the cells. Uncovering the cell types in which this DRD2/STAT3/IL-6 pathway can 
be targeted would be an important step in determining which tumors can be most effectively 
treated with thioridazine or other DRD2-targeting antipsychotics. 
The STAT3/IL-6 activation loop is an established cancer promoting pathway. High 
systemic IL-6 correlates with poorer prognosis and advanced tumor stage in breast cancer 
patients (Dethlefsen et al., 2013), and STAT3 is known to promote breast cancer survival, 
invasion, drug resistance and stemness (Banerjee and Resat, 2016; Real et al., 2002; 




research into targeting the STAT3/IL-6 pathway. However, STAT3, like many transcription 
factors, has proven difficult to specifically target with small compounds. Although antibodies 
that target both IL-6 and the IL-6 receptor have been developed and have made major 
impacts in inflammation-related diseases, translation into cancer therapies has been slow 
(Heo et al., 2016). Mechanisms whereby inhibiting DRD2 has anti-cancer effects remain 
largely unknown. Here we demonstrate that DRD2 promotes STAT3 activation and that 
thioridazine and other DRD2-targeting compounds blocks that activity in SUM149 cells. Using 
tumorsphere assays, we also show that STAT3 is required for DRD2 to promote self-renewal, 
and thioridazine does not block self-renewal in the absence of STAT3 in SUM149 cells. We 
observed the strongest decrease of pY705-STAT3 at 5-10µM thioridazine. At these doses loss 
of cell viability is observed, not just self-renewal defects. However, these western blots were 
performed after 1 hour of treatment from cells grown adherently. We also show that addition 
of recombinant IL-6 rescues tumorsphere number of thioridazine-treated and shDRD2 
SUM149 cells. IL-6 treatment is also still able to increase pY705-STAT3, even with 
thioridazine-treatment or in DRD2 knockdown cells. This indicates that IL-6 is downstream of 
DRD2/STAT3, and that DRD2 likely supports STAT3 activity, and IL-6 is subsequently 
promoted via increased STAT3 activity.  
Notably, we demonstrated that thioridazine induces a G1 arrest and a decrease in cell 
proliferation that is independent of DRD2/STAT3 in SUM149 cells. We also determined that 
5µM thioridazine causes a reduction in proliferation without a dramatic increase in apoptosis. 
(Figure 2.2 and 2.4). We also show using DRD2-CRISPR cells and the highly specific DRD2/3 
inhibitor amisulpride that DRD2 does not support proliferation and viability in the bulk of 
tumor cells (Figure 2.15C and D). Importantly, we demonstrate that thioridazine is not 
dependent on the presence of DRD2 to inhibit proliferation in SUM149 cells (Figure 2.15E). 
This is supported by work from Kline et al, which showed that a novel DRD2 antagonist, 




cancer cells (Kline et al., 2018). The mechanisms by which these DRD2-independent effects 
occur are unknown, but they may offer insight into interesting new drug targets for TNBC. 
The origin of an activating ligand in cancer, if any, for DRD2 is still unknown. The 
catecholamine dopamine is generally considered the primary activator for all dopamine 
receptors, including DRD2 (Missale et al., 1998). It is unknown what the potential source of 
dopamine could be in the breast cancer milieu. Interestingly, T-cells, B-cells, dendritic cells, 
and macrophages have all been shown to express dopamine receptors (Levite, 2016; 
McKenna et al., 2002). These cells have been shown to be capable of dopamine synthesis 
(Bergquist et al., 1994; Josefsson et al., 1996; Kokkinou et al., 2009; Levite, 2016; Nakano 
et al., 2009), and dopamine has been demonstrated to either promote or inhibit their activity 
(Cosentino et al., 2007; Josefsson et al., 1996; Levite, 2016; McKenna et al., 2002; Nakano 
et al., 2009). It is possible that tumor infiltrating immune cells could secrete dopamine and 
other catecholamines and support tumor growth and/or suppress antitumor immunity. 
However, our study is based on cell lines grown in vitro. So even if infiltrating immune cells 
are a source of dopamine in vivo, dopamine receptors have cancer cell line autonomous 
effects. Whether this is a result of intrinsic, ligand-independent, activity of dopamine receptors 
or whether cancer cells themselves maybe secreting dopamine is unclear. Additionally, there 
is evidence that proteins, such as the non-canonical Wnt5a, can also activate DRD2 (Yoon et 
al., 2011). The implications of this are intriguing, but mostly unexplored.  
It is also unknown which cell types are most sensitive to thioridazine and other DRD2-
targeting compounds. We show that the self-renewal of several TNBCLs (SUM149, HCC1143, 
HCC1937) is strongly inhibited by thioridazine, whereas the self-renewal of three other 
TNBCLs (SUM159, MDA-MB-231, HCC38) is unaffected by thioridazine (Figure 2.2B). The 
inhibition of self-renewal caused by 1µM thioridazine is dependent on DRD2 (Figure 2.15A 
and B). Interestingly, we also show that while the TNBCLs in which thioridazine inhibits self-




(Figure 2.7A). Further, thioridazine inhibits STAT3 activation in SUM149 cells, but not SUM159 
cells (Figure 2.7D), and STAT3 is required for thioridazine to inhibit self-renewal in SUM149 
cells (Figure 2.8). These findings suggest that some cell types, as in SUM149 cells, the DRD2 
promotes STAT3/IL-6 activity to support self-renewal, whereas in other cell types, as in 
SUM159 cells, STAT3 activity is not supported by DRD2 and therefore DRD2 inhibition does 
not block self-renewal. The effects of thioridazine on STAT3 activation and tumor growth of 
the murine 4t1 triple-negative breast cancer model have already been tested. Although 4t1 
tumor growth is suppressed by thioridazine treatment, STAT3 phosphorylation is unaffected 
(Yin et al., 2015). This is similar to the effects of thioridazine on the TNBCL SUM159. The 
connection between DRD2 activity and STAT3/IL-6 needs to be explored further to determine 
the cell types in which targeting DRD2 is likely to lead to a specific inhibition of self-renewal. 
We show that the effects of thioridazine on proliferation and cell viability are 
independent of DRD2. Finding the receptors responsible for these effects may be important, 
but complicated as thioridazine is known to bind other GPCRs (Besnard et al., 2012). 
Interestingly, antagonism of serotonergic receptors has been shown to reduce breast cancer 
growth (Gwynne et al., 2017). Important roles of adrenergic receptors in promoting 
progression and angiogenesis of prostate cancer have also been recently reported (Magnon 
et al., 2013; Zahalka et al., 2017). Additionally, a recent study showed that treatment of 
glioblastoma cells with DRD4 antagonists inhibited autophagy, led to a G1 arrest, and 
ultimately induced apoptosis (Dolma et al., 2016). This implicates DRD4 as potentially 
regulating cancer cell survival in glioblastoma. However, mechanisms by which antipsychotics 
like thioridazine can achieve such dramatic effects across so many cell types remain elusive. 
This study has shown that DRD2 can promote STAT3 activity and self-renewal, and 
antipsychotics that preferentially target DRD2 can inhibit this pathway in SUM149 cells. 
Interestingly, these antipsychotics also have strong effects on cell proliferation and cell 




generally safe and has shown to be potent at reducing cancer cell viability, and there may be 
potential therapeutic benefit to using thioridazine or other DRD2-targeting compounds in the 
cancer clinic. 
2.4 – Experimental Procedures 
Cell culture and reagents 
SUM149 and SUM159 cells were maintained in HuMEC medium (Gibco, Waltham, MA, 
USA) with 5% fetal bovine serum (FBS). MDA-MB-231 cells were maintained in DMEM (Gibco) 
with 10% FBS. HCC38, HCC1143, and HCC1937 cells were maintained in RPMI-1640 with 
10% FBS. Thioridazine, chlorpromazine, forskolin, amisulpride, and quinpirole were obtained 
from (Sigma-Aldrich, St. Louis, MO, USA). All antibodies were obtained from Cell Signaling 
Technologies (Danvers, MA, USA). qPCR primer-probe sets targeting IL-6 and GUSB were 
obtained from Applied Biosystems (Grand Island, NY, USA). DRD2 primer-probe set was 
obtained from Bio-Rad (Hercules, CA, USA) Recombinant IL-6 was obtained from Peprotech 
(Rocky Hill, NJ, USA). Anti-IL-6 receptor antibody was obtained from R & D Systems 
(Minneapolis, MN, USA). All siRNAs were SMARTpool siGENOME from Dharmacon (Lafayette, 
CO, USA). DRD2 overexpression plasmid in pLENTI6-V5 vector was obtained from the CCSB 
- Broad lentiviral ORF collection (Yang et al., 2011). 
 
Stable shDRD2 and DRD2-CRISPR cell lines 
DRD2-targeting shRNA constructs (TRCN0000011342 and TRCN0000011343) in 
pLKO.1 vector backbone was obtained from the Open Biosystems TRC1 shRNA library. The 
plasmids were transfected into HEK293T cells using FuGeneHD (Promega, Madison, WI, USA). 
The supernatant was collected then filtered using 0.4μm filters. The resulting liquid was then 
concentrated to approximately 150μL using Amicon Ultra-15 Ultracel-100 (Millipore, Billerica, 
MA, USA). The virus concentrate was then added to SUM149 cell growing in 10 mL of HuMEC 




plasmid #52961). Genomic sequences to target were identified using predictive software from 
the Zhang lab. Sequences of the primers to clone the DRD2 CRIPSR constructs are as follows: 
5’-CTGCGTTATTGAGTCCGAAG-3’ and 5’-GTAGCGCGTATTGTACAGCA-3’. Lentivirus was made 
as previously stated. Pooled CRISPR mutants that survived puromycin selection were used for 
experiments. 
 
Immunoblots, cell fractionation, and immunoprecipitation 
Immunoblots and immunoprecipitations were performed as previously described (Hsia 
et al., 2017), except Mini-PROTEAN TGX SDS-PAGE gels (Bio-Rad) and Clarity ECL (Bio-Rad) 
were used. To obtain nuclear and cytoplasmic extracts cells were lysed with CE buffer (10mM 
HEPES, 60mM KCl, 1mM EDTA, 0.075% NP-40, 1mM DTT and protease and phosphatase 
inhibitor cocktails). Cytoplasmic extract was removed and the resulting nuclei were washed 
in CE buffer then lysed in NE buffer (62.5mM Tris-HCl, 5% glycerol, 2% SDS, 5% β-
mercatoethanol). The lysates were then immunoblots as described. 
 
RNA isolation and quantitative PCR 
Total RNA was isolated using Trizol (Invirogen) according to manufacturer’s protocol. 
iScript (Bio-Rad) was used to make cDNA. Quantitative PCR was performed with iTaq Probes 
Supermix (Bio-Rad) using an QuantStudio 6 (Applied Biosystems, Foster, CA, USA) and 




Cells were trypsinized and resuspended into a single cell suspension and counted using 
a hemocytometer. 20000 cells were resuspended in 2 mL of complete mammocult medium 




(Corning, Corning, NY, USA). After one week of culture, the spheres were collected and all 
spheres greater than 60μm in diameter were counted according to manufacturer’s protocol 
(Stem Cell Technologies). Secondary tumorsphere formation was assessed by culturing 
primary spheres as described; the resulting spheres were dissociated with trypsin and 20000 
cells were again plated in 2mL of complete mammocult into ultra-low adherence 6 well plates. 
Thioridazine treatments were applied once at the time of plating. Quinpirole, chlorpromazine, 
amisulpride, rIL-6, and anti-IL-6R antibody were applied daily. Experiments with siDRD2 were 
performed as described except only 200 cells were plated in 2mL of mammocult. 
 
Transfections 
Overexpression analysis was achieved by transfecting 10μg of plasmid with 20μL of 
FugeneHD (Promega). siRNA transfections were achieved by using 40nM siRNA and 
DharmafectI (Dharmacon) according to manufacturer’s protocol. 
 
Proliferation, cell viability, and caspase assays 
To assess proliferation, cells were plated in 24 well plates at 4000 cells per well in 
triplicate (SUM159), or 6500 cells per well in triplicate (SUM149). Cells were counted at 
indicated times using a hemocytometer. Cell viability assays were performed by plating 1000 
cells in a 96 well plate in medium with the appropriate concentration of thioridazine.  After 72 
hours, cells were treated with 100μL of CellTiterGlo (Promega) for 10 minutes. Luciferase 
activity was measured using a Synergy 2 Luminometer (BioTek, Winooski, VT, USA). IC50 was 
determined using GraphPad Prism 5 (Prism, La Jolla, CA, USA). To asses caspase 3/7 activity, 
2500 SUM149 cells were plated per well in a 96 well plate and treated with indicated 
concentrations of thioridazine for 4, 24, or 48hr. Assay was performed according to 






Cell cycle analysis 
SUM149 cells were treated with DMSO or thioridazine for 48 hours and fixed in ice-
cold 70% ethanol for 2 hours at 4oC. The cells were resuspended in flow buffer (1x PBS, 10% 
FBS) and treated with 10μg/mL RNase A for 30 minutes at 37oC. 5μL of 1mg/mL propidium 
iodide (Invitrogen) was added for 30 mins at room temperature. Cells were then washed in 
flow buffer and filtered using a 40μm filter (BD). Data were aquired using a Cyan ADP Flow 
Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using FloJo software 
(Ashland, Oregon, USA). 
 
ELISA 
To measure soluble IL-6, fresh HuMEC medium with DMSO or thioridazine was added 
to SUM149 cells in 6 well plates. 4 hours later, the medium was collected and centrifuged to 
remove insoluble material. Then the human IL-6 BD OptEIA kit was used to detect the IL-6 
according to manufacturer’s protocol (Becton Dickinson). To measure cAMP, cells in a 6 well 
plate were treated with 1μM forskolin and either DMSO or quinpirole. Cells were additionally 
treated with 2μM thioridazine where indicated. After a 15-minute incubation, the cells were 
harvested and ELISA was performed according to manufacturer’s protocol using the Cyclic 
AMP Select ELISA Kit (Cayman Chemical, Ann Arbor, MI, USA).  
 
TCGA analysis 
Expression of DRD2 across breast cancer subtypes was analyzed in the breast invasive 
carcinoma samples in the TCGA dataset. A one-way ANOVA was performed to compare the 






Statistical significance tests were done as described in each figure. GraphPad Prism 7 




















Figure 2.1 - DRD2 Expression across breast cancer subtypes. Log2 gene expression of 
DRD2 (Entrez gene ID 1819) is displayed for each breast cancer subtype by with boxplots. 
(Basal = basal-like breast cancer; CLOW = claudin-low; Her2 = Her2 amplified; ILC = lobular 











Figure 2.2 - Thioridazine inhibits self-renewal is some TNBCLs, but not others, while 
it inhibits proliferation and cell viability in all TNBCLs. (A) SUM149, HCC1143, 
HCC1937, SUM159, MDA-MB231, and HCC38 cells were cultured in a tumorsphere assay with 
DMSO, 1μM, 2μM, or 5μM thioridazine. (B) SUM149 and SUM159 cells were cultured as 
spheres in DMSO, 0.5μM, 1μM, or 2μM thioridazine. After 7 days, spheres were dissociated, 
and cultured again as spheres in the presence of the same concentrations of thioridazine 
before the number of spheres was counted 7 days later. (C) Total RNA was harvested from 
SUM149, HCC1143, HCC1937, SUM159, MDA-MB231, and HCC38 cells, cDNA was made, and 
DRD2 mRNA was measured by qPCR. The relative expression of each cell line is normalized 
to SUM149 expression. (D) SUM149, HCC1143, HCC1937, SUM159, MDA-MB231, and HCC38 
cells were treated with DMSO, 1μM, 2μM, 4μM, 8μM, 16μM, or 32μM thioridazine for 72 hours. 
CellTiter-Glo was used to measure cell viability. (E) Top SUM149 cells were treated with 
DMSO, 1μM, 2μM, or 5μM thioridazine and cells were counted every 24 hours. Bottom As in 
top, but 5μM thioridazine curve only is shown. (F) Top SUM159 cells were treated with DMSO, 
1μM, 2μM, or 5μM thioridazine and cells were counted every 24 hours. Bottom As in top, but 
5μM thioridazine curve only is shown. All experiments where performed with three biological 
replicates. Significance for (C) was measured using a two-sample t-test, significance for (E) 
and (F) was measured by repeated measures ANOVA, and significance for all other 
experiments was measured using a one-sample t-test. Error bars represent standard 





Figure 2.3 - Increased DRD2 expression in sphere-forming cells. (A) SUM149 cells 
were cultured as spheres or adherently. Total RNA was collected and DRD2 expression was 
determined using quantitative PCR. (B) SUM159 cells were cultured as spheres or adherently. 
Total RNA was collected and DRD2 expression was determined using quantitative PCR. All 
experiments were performed with three biological replicates. Significance is measured using 






















Table 2.1 - IC50 of thioridazine in 6 TNBCLs. The IC50 of thioridazine in each cell line from 
the cell viability assay in (Figure 2.2C) is shown. GraphPad Prism software was used to 























Figure 2.4 - Low doses of thioridazine do not induce apoptosis. (A) SUM149 cells were 
treated with thioridazine at the indicated concentrations for 48 hours. Cells were stained with 
propidium iodide and analyzed by flow cytometry to determine cell cycle stage. (B) SUM149 
cells were treated with the indicated concentrations of thioridazine for 24hr, and apoptosis 
was measured using Caspase-Glo 3/7 Assay. (C) SUM149 cells were treated with DMSO, 1μM, 
2μM, or 5μM thioridazine and cultured for 24 hours. Cells were then harvested and full length 
and cleaved PARP-1 abundance was measured by western blot. All experiments where 
performed with three biological replicates. Significance for (A) was measured using a two-
sample t-test, and significance for (B) was measured using a one-sample t-test. Error bars 





























Figure 2.5 - Thioridazine treatment does not induce TRAIL production via AKT 
inhibition and Foxo3a activation. (A) SUM149 cells were treated with the indicated 
concentrations of thioridazine for 1 hour. Protein lysates were harvested and abundance of 
pT308-AKT, total AKT, and actin was measured by western blot. (B) SUM149 cells were 
treated with 5μM thioridazine for the indicated timepoints. Nuclear extracts were made and 
Foxo3a abundance was measured by western blot. Histone H3 was used to measure nuclear 
isolation quality and loading, and tubulin was used to measure cytoplasmic purity. The 
quantifications are the fold-change of relative Foxo3a normalized to H3. (C)  SUM149 cells 
were treated with 5μM thioridazine for the indicated timepoints, total RNA was isolated, and 
TRAIL mRNA abundance was measure by quantitative PCR. All experiments were performed 









Figure 2.6 - Thioridazine induces G1 arrest. (A) SUM149 cells were treated with DMSO, 
1μM, 2μM, or 5μM thioridazine for 48 hours. Cells were stained with propidium iodide and 
analyzed by flow cytometry to determine cell cycle stage. (B) Quantification of cell cycle stage. 
FloJo software was used to classify cell cycle stage. (C) SUM149 cells were treated with 5µM 
thioridazine for indicated lengths of time. Cells were harvested and abundance of p21, 
CyclinD1, CDK4, and Actin proteins were measured by western blot. All experiments were 
performed with three biological replicates and representative images are shown. Significance 
































Figure 2.7 - Thioridazine inhibits STAT3 activity and IL-6 production. (A) Quantitative 
PCR analysis of relative IL-6 mRNA abundance in 6 TNBCLs. The relative expression of each 
cell line is normalized to SUM149 expression. (B) SUM149 cells were treated with 5μM 
thioridazine for the indicated timepoints, total RNA was isolated, and IL-6 mRNA abundance 
was measure by quantitative PCR. (C) The medium of SUM149 cells was replaced with fresh 
medium containing either DMSO or the indicated concentration of thioridazine. After 4 hours, 
the media were harvested and secreted IL-6 protein was measured by ELISA. (D) SUM149 
and SUM159 cells were treated with DMSO, 1µM, 2µM, 5µM, or 10µM thioridazine for one 
hour. Protein lysates were harvested and abundance of pY705-STAT3 was measured by 
western blot. (E) SUM149 cells were treated with 5μM thioridazine for the indicated 
timepoints. Nuclear extracts were made and STAT3 abundance was measured by western 
blot. Histone H3 was used to measure nuclear isolation quality and loading, and tubulin was 
used to measure cytoplasmic purity. (F) Quantification of nuclear pY705-STAT3 and total 
STAT3. The quantifications are the fold-change of relative pY705-STAT3 and STAT3 
normalized to H3. All experiments were performed with three biological replicates. 
Significance for (A) is measured using a two-sample t-test, significance for other experiments 








Figure 2.8 - Thioridazine inhibits self-renewal, but not cell viability via STAT3/IL-6. 
(A) Left SUM149 cells were transfected with either siControl or siSTAT3 and then cultured in 
a tumorsphere assay. Each group was also treated with DMSO or 1μM thioridazine and 
tumorspheres were counted after 7 days. Right STAT3 knockdown is shown. (B) Left SUM149 
cells were cultured in a tumorsphere assay, treated with DMSO or 1μM thioridazine. Each 
group was additionally treated with mock solution or 60ng/mL rIL-6 for 7 days and spheres 
were counted. Right Quantification of the fold change in sphere formation induced by rIL-6 
treatment. (C) Left SUM149 cells were treated with 5µM thioridazine for 5 min., 60ng/mL 
recombinant IL-6 was added for 10 min., and protein abundance was measured by western 
blot. Right Quantification of the fold change in relative pY705-STAT3 signal induced by rIL-6 
treatment. (D) SUM149 cells were transfected with either siControl or siSTAT3 and then 
cultured adherently. Each group was also treated with DMSO 1μM, 2µM, or 5µM thioridazine 
and cells were counted after 72 hours. All experiments were performed with three biological 
replicates. Significance for (A) and (B) was measured using a one-sample t-test. Significance 














Figure 2.9 - DRD2 promotes self-renewal. (A) SUM149 cells were treated with siControl 
or siDRD2 and cultured in a tumorsphere assay for one week, and the number of spheres 
formed was counted. (B) SUM159 cells were treated with siControl or siDRD2 and cultured in 
a tumorsphere assay for one week, and the number of spheres formed was counted. (C) 
SUM149 cells stably expressing a control or DRD2-targeting shRNA were cultured in a 
tumorsphere assay for one week, then the number of spheres formed was counted. (D) 
SUM149 cells stably expressing a control or DRD2-targeting CRISPR/Cas9 construct were 
cultured in a tumorsphere assay for one week, then the number of spheres formed was 
counted. (E) Secondary tumorsphere formation of SUM149 cells stably expressing a control 
or DRD2-targeting CRISPR/Cas9 contruct. (F) SUM149 cells were treated with DMSO, 1µM, 
2µM, or 5µM chlorpromazine once. 7 days later the number of spheres formed where counted. 
(G) SUM149 cells were treated with DMSO, 250nM, 500nM, or 1µM amisulpride daily in a 
tumorsphere assay for week before the number of spheres formed was assessed. (H) SUM149 
cells were treated with DMSO, 5µM, 15µM, or 50µM quinpirole daily in a tumorsphere assay 
for week before the number of spheres formed was assessed. All experiments were performed 
with three biological replicates and significance was measured using one-sample t-test. Error 









Figure 2.10 - DRD2 mRNA in knockdown cells. (A) Relative abundance of DRD2 mRNA 
was measured by qPCR. (B) Total RNA from SUM149 control and DRD2-CRISPR cells, and 
relative abundance of DRD2 mRNA was measured by qPCR. (C) Total RNA from SUM149 
control and siDRD2 cells, and relative abundance of DRD2 mRNA was measured by qPCR. (D) 
Total RNA from SUM159 control and siDRD2 cells, and relative abundance of DRD2 mRNA was 
measured by qPCR. All RNA was measured from three independent RNA collections and qPCR 


















Figure 2.11 - gDNA mutation in DRD2 CRIPSR cells. Genomic DNA was extracted from 
SUM149 CRISPR A and SUM149 CRISPR B cells. The region surrounding DRD2 exon 3 was 
amplified by PCR and column purified before sanger sequencing was performed to determine 





Figure 2.12 - DRD2 promotes STAT3 activity. (A) SUM149 cells were treated with DMSO, 
1µM, 5µM, 10µM, or 20µM chlorpromazine for one hour. Protein lysates were harvested and 
abundance of pY705-STAT3 was measured by western blot. (B) SUM149 cells were treated 
with DMSO, 500nM, 1µM, or 2µM amisulpride for 18 hours. Protein lysates were harvested 
and abundance of pY705-STAT3 was measured by western blot. (C) DRD2 was overexpressed 
in SUM159 cells, which were then treated with 5μM thioridazine for 1 hour. pY705-STAT3 was 
measured by western blot. (D) SUM149 cells were cultured as spheres for 7 days. The sphere 
cultured was treated with 1µM thioridazine for 0, 0.5, 1, or 2 hours. pY705-STAT3 was 
measured by western blot. All experiments were performed with three biological replicates 

















Figure 2.13 - DRD2 knockdown with RNAi does not consistently decrease pY705-
STAT3. (A) SUM149 cells were treated with siControl or siDRD2 (n =4) and pY705-STAT3 
abundance compared to total STAT3 was measured by western blot and relative 
quantifications were performed. (B) SUM149 shDRD2 cells harvested (n = 3) and pY705-
STAT3 abundance compared to total STAT3 was measured by western blot and relative 



















Figure 2.14 - IL-6 is downstream of DRD2 in SUM149 cells. (A) SUM149 pLKO and 
shDRD2 cells were cultured in a tumorsphere assay for 7 days and treated with a mock 
solution or 60ng/mL rIL-6 daily. (B) Top SUM149 pLKO and shDRD2.1 cells were treated with 
60ng/mL rIL-6 for 30min. Cells were then harvested and abundance of pY705-STAT3 was 
measured by western blot. Bottom SUM149 pLKO and shDRD2.2 cells were treated with 
60ng/mL rIL-6 for 30min. Cells were then harvested and abundance of pY705-STAT3 was 
measured by western blot. Experiments were performed in triplicate. Significance was 














Figure 2.15 - Thioridazine inhibits self-renewal, but not cell viability via DRD2 
inhibition. (A) SUM149 cells were transfected with either siControl or siDRD2 and then 
cultured in a tumorsphere assay. Each group was also treated with DMSO or 1μM thioridazine 
and tumorspheres were counted after one week. (B) Control and DRD2-CRISPR SUM149 cells 
were cultured in a tumorsphere assay, treated with DMSO or 1μM thioridazine and the number 
of spheres formed was counted after one week. (C) SUM149 DRD2-CRIPSR cells were seeded 
and the number of cells were counted after 72 hours. (D) SUM149 cells were seeded and 
treated with the indicated concentration of amisulpride. Cells were then counted after 72 
hours. (E) SUM149 control or DRD2-CRISPR cells were treated with DMSO 1μM, 2µM, or 5µM 
thioridazine and cells were counted after 72 hours. (F) Model figure describing mechanism of 
thioridazine effects on TNBCLs. All experiments were performed with three biological 
replicates. Significance for (E) is measured using a two-sample t-test, significance for other 
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CHAPTER 3: SPECULATIVE STUDIES SUGGEST THAT ACTIVE DOPAMINE 
SIGNALING IN BASAL-LIKE BREAST CANCER CELLS VIA ACTIVATION OF 
PLASMINOGEN PATHWAY MAY PROMOTE SELF-RENEWAL 
3.1 – Introduction 
 Despite advances in screening and targeted therapies, breast cancer is the most 
common malignancy in women, and the second most common cause of cancer-related deaths 
in women (Siegel et al., 2018). Addressing the treatment of breast cancers is complicated as 
it is not a single, homogenous disease. Rather, there are at least 5 types of breast cancer, 
termed subtypes, based on molecular gene expression (Luminal A, Luminal B, HER2+, Basal-
like, and Claudin-low) (Herschkowitz et al., 2007; Perou et al., 2000). These subtypes not 
only describe intrinsic molecular characteristics, but they also hold prognostic value and 
correlate with known responses to different therapies (Brenton et al., 2005; Sørlie et al., 
2001). While luminal tumors usually express estrogen receptor and are responsive to 
hormone therapies, and HER2+ tumors overexpress the HER2 receptor and usually respond 
to HER2-targeted therapies, many basal-like and claudin-low tumors do not express these 
receptors, and as such there are no targeted therapies to treat these tumors (Brenton et al., 
2005; Foulkes et al., 2010; Sørlie et al., 2001). While basal-like tumors do respond well to 
chemotherapy, recurrence is still elevated in this group compared to other subtypes, and 
metastatic disease for all subtypes remains an unsolved problem decades after diagnosis 
(Haque et al., 2012; Prat and Perou, 2011). 
 Despite increased awareness and targeted therapies, over 40,000 people die of breast 
cancer each year in the US alone (Siegel et al., 2018), and metastatic disease is the primary 




population of tumor cells, cancer stem cells (CSCs), are capable of indefinite self-renewal and 
colonization of distant sites (Clevers, 2011; Reya et al., 2001). This colonization activity can 
be measured in vitro using the tumorsphere assay, in which a population of cells are cultured 
in suspension at low density and without serum, thus limiting survival and proliferation signals 
from surface and cell-to-cell attachment, as well as from factors in serum. 
The plasminogen pathway is known for its roles in thrombosis and clearing blood clots 
and fibrous tissue (Bezerra et al., 1999; Mekkawy et al., 2014), however, high expression of 
important plasminogen pathway genes is also associated with poor outcomes and metastasis 
in breast cancer (Andreasen et al., 1997). The plasminogen pathway ultimately leads to the 
proteolytic processing of plasminogen to plasmin, an active protease in the extracellular 
matrix through the activity of one of two activators (PLAT/tPA or PLAU/uPA) (Andreasen et 
al., 1997). Plasmin and its activation can be blocked by SERPINE1/PAI-1, a serine protease 
inhibitor (Andreasen et al., 1997). Although this pathway is associated with poor outcomes 
and metastasis in breast cancer, the mechanisms by which this occurs are not precisely 
known, but are presumed to be dependent on the degradation of the extracellular matrix 
(Andreasen et al., 1997; Li et al., 2018; Mekkawy et al., 2014; Schmitt et al., 2011). However, 
activated plasmin has also been shown to support the release of dopamine in cultured neurons 
and in vivo (Bahi et al., 2008; Ito et al., 2006; Nagai et al., 2004, 2005). In fact, 
depolarization-induced dopamine release was completely abrogated in neurons from tPA-/- 
mice (Ito et al., 2006). The plasmin pathway is not only associated with poor survival and 
metastasis in breast cancer, but it also supports the release of dopamine in neurons. 
Dopamine is a catecholamine neurotransmitter that, when released from cells, can 
bind and activate dopamine receptors. Dopamine signaling via dopamine receptors has been 
shown to regulate numerous neurological processes and diseases from locomotion, learning, 
and memory to addiction, Parkinson’s disease, and schizophrenia (Beaulieu et al., 2015; 




functions of dopamine. Many drugs targeting DRD2 in particular have been developed, as all 
drugs with antipsychotic activity inhibit DRD2 (Kapur and Seeman, 2001; Seeman, 2006).  
However, dopamine signaling is not restricted to neurons, and many peripheral 
functions have been elucidated. DRD2 has been shown to modulate blood pressure by 
regulating sodium secretion in the kidneys (Chugh et al., 2013; Hussain and Lokhandwala, 
2003), inhibit prolactin secretion in the pituitary (Kebabian and Calne, 1979), and regulate T-
cell activation and proliferation, among other functions (Basu et al., 2010; Levite, 2016; 
Missale et al., 1998). 
 Although thioridazine and pimozide, which are both DRD2-targeting antipsychotic 
drugs, were shown to reduce the proliferation of cultured cancer cells nearly 30 years ago 
(Strobl and Peterson, 1992; Strobl et al., 1990), the effects of these drugs on cancer cells 
went largely unexplored until a small molecule screen identified thioridazine as an inhibitor of 
cancer stem cells (Sachlos et al., 2012). Since that publication, several studies have shown 
that DRD2-targeting antipsychotics can reduce growth, induce apoptosis, or even inhibit self-
renewal in many cancer cell types including leukemia, glioblastoma, colorectal, lung, and 
breast cancer cell lines (Cheng et al., 2015; Li et al., 2014; Sachlos et al., 2012; Yin et al., 
2015; Yue et al., 2016; Zhang et al., 2016). Recently, work from our own lab has shown that 
the inhibition of proliferation at higher doses of thioridazine (5µM) in triple-negative breast 
cancer cells occurs independent of DRD2-inhibition, while the inhibition of self-renewal at 
lower doses (1µM) is mediated through the inhibition of DRD2 and STAT3 activity (Tegowski 
et al., 2018). That study also demonstrated that the self-renewal of some breast cancer cell 
lines could be inhibited by thioridazine, while others were unaffected. 
 In this chapter, we present evidence that the self-renewal of basal-like breast cancer 
cell lines is most sensitive to thioridazine in vitro, while the self-renewal of cell lines from 
other subtypes is more resistant. We also demonstrate that DRD2 expression can be detected 




We postulate that DRD2 regulation may depend on dopamine release regulated by the 
plasminogen pathway, which may be more highly active in basal-like cells. Activation of this 
pathway in luminal or claudin-low cell lines could potentially support self-renewal in a manner 
that is sensitive to thioridazine.  
3.2 – Results 
3.2.1 – Thioridazine preferentially targets the tumorsphere initiating cells of basal-like breast 
cancer cell lines (BLBCLs) 
 Previous work from our lab has shown that 1µM thioridazine decreases self-renewal in 
two BLBCLs, HCC1143 and SUM149 cells, but not in claudin-low breast cancer cell lines 
(CLBCLs) SUM159, MDA-MB-231, and HCC38 cells (Chapter 2). To determine if thioridazine 
preferentially inhibits self-renewal in the basal-like subtype, we also tested the effects of 
thioridazine on the tumorsphere formation in two luminal cell lines (MCF7 and ZR751), two 
HER2+ cell lines (MDA-MB-361 and BT474), as well as another basal-like cell line (SUM229), 
and compared the results to the effects previously reported in Chapter 2. Strikingly, 1µM or 
2µM thioridazine did not decrease tumorsphere formation in any luminal, HER2+, or claudin-
low cell lines (Figure 3.1A). However, doses as low as 1µM thioridazine did reduce 
tumorsphere formation in 3 out of 4 BLBCLs (HCC1143, SUM149, and SUM229) (Figure 3.1A). 
Since the formation of visible spheres can be inhibited by reduced proliferation as well as by 
the inhibition of self-renewal, we also tested the effects of thioridazine on the proliferation of 
adherently growing cells. Except for ZR751 cells, 1µM thioridazine did not significantly 
decrease adherent proliferation in any cell lines (Figure 3.1B). This suggests that the observed 
differences in tumorsphere formation at 1µM thioridazine are from effects on self-renewal, not 
from confounding effects on proliferation. Remarkably, the proliferation of all cell lines was 
strongly decreased at 5µM thioridazine, regardless of whether tumorsphere formation was 
affected at the same concentration (Figure 3.1B). This suggests that thioridazine can inhibit 




that thioridazine preferentially decreases tumorsphere formation in BLBCLs, but not in other 
subtypes. 
Although cell line models are far more homogenous than a tumor microenvironment, 
some cell lines stably exist with multiple populations of cells that have different 
characteristics. In particular, SUM229 and SUM149 BLBCLs consist of a major population of 
epithelial, basal-like cells, and a subpopulation of mesenchymal, claudin-low cells (Prat et al., 
2013). The epithelial basal-like population is EpCAM+, while the mesenchymal claudin-low 
population is EpCAM- (Prat et al., 2013). We obtained SUM229 cells sorted into EpCAM+ and 
EpCAM- populations and confirmed the EpCAM expression in each population (Figure 3.2C). 
We tested whether the tumorsphere formation of the EpCAM+ basal-like population of cells is 
more sensitive to thioridazine treatment than the EpCAM- claudin-low population within the 
same cell line. Indeed, while thioridazine dose-dependently decreases tumorsphere formation 
in EpCAM+ SUM229 cells, the number of tumorspheres formed is unaffected, even at doses 
as high as 5µM thioridazine in the EpCAM- cells (Figure 3.2A). Despite this dramatic difference, 
thioridazine inhibits adherent proliferation similarly in both EpCAM+ and EpCAM- cells (Figure 
3.2B). To further test whether the self-renewal of basal-like cells is more sensitive than 
claudin-low cells, we measured tumorsphere formation in SUM149 cells sorted into EpCAM+ 
and EpCAM- populations (Figure 3.2F). Similar to SUM229 cells, thioridazine inhibits 
tumorsphere formation in SUM149 EpCAM+ at doses as low as 1µM, but not in SUM149 EpCAM- 
cells (Figure 3.2D). Unlike SUM229 cells however, 5µM thioridazine almost completely blocks 
tumorsphere formation, as well as proliferation, in both EpCAM+ and EpCAM- populations 
(Figure 3.2D and E). This suggests that thioridazine affects proliferation and cell viability in 
all SUM149 cells, regardless of EpCAM status, more strongly than in SUM229 cells. The 
inhibition of proliferation and cell viability is independent of the effects of DRD2 on self-




Thioridazine decreased tumorsphere formation most potently in cell line classified as 
basal-like breast cancer cell lines, and within triple-negative breast cancer cell lines, 
thioridazine inhibited tumorsphere formation most potently in the EpCAM+ cells. Together, 
these data show that thioridazine targets self-renewal most potently in basal-like breast 
cancer cells. 
3.2.2 DRD2 expression does not predict thioridazine effects on self-renewal 
 Since self-renewal of 3 out of 4 BLBCLs is most sensitive to thioridazine, and this effect 
is thought to be DRD2-dependent, we reasoned that DRD2 expression would be highest in 
the BLBCLs. Further, previously reported analysis of TCGA data indicated that DRD2 mRNA 
expression is elevated in basal-like breast cancers (Chapter 2). So, we measured DRD2 mRNA 
expression by qPCR, and DRD2 expression was indeed observed to be higher, on average, in 
BLBCLs, than in non-BLBCLs (Figure 3.3A). It is noteworthy that DRD2 expression could be 
detected in all cell lines tested, regardless of subtype (Figure 3.3B). Further, SUM149 cells, 
which are highly sensitive to thioridazine in the tumorsphere assay, do not highly express 
DRD2 mRNA, relative to the other BLBCLs (Figure 3.3B). In fact, SUM149 cells express lower 
levels of DRD2 mRNA than several other cell lines whose self-renewal is not sensitive to 
thioridazine, like HCC38 cells or SUM159 cells (Figure 3.3B).  Additionally, although SUM229 
EpCAM+ cells express more DRD2 mRNA than SUM229- cells, SUM149 EpCAM+ cells do not 
express more DRD2 mRNA (Figure 3.3C and D). This suggests that while DRD2 mRNA 
expression is generally higher in most basal-like cells, DRD2 mRNA expression alone does not 
predict whether thioridazine can inhibit tumorsphere formation in a specific cell line. 
 We also analyzed DRD2 protein expression by immunoblot. We first confirmed that the 
DRD2 antibody showed specificity for DRD2 by performing immunoblots on siControl and 
siDRD2-treated cells (Figure 3.4). When DRD2 protein abundance in all 11 cell lines was 
compared the highest expression of DRD2 protein was observed in luminal and claudin-low 




confirms that simply measuring DRD2 expression alone, does not predict sensitivity to 
thioridazine.  
3.2.3 DRD2 activation promotes sphere formation in non-basal like cells 
 Since DRD2 mRNA and protein expression was observed in all breast cancer cell lines 
tested, we speculated that perhaps DRD2 may be expressed but not active in cell lines whose 
self-renewal is not affected by thioridazine. To test this, we measured tumorsphere formation 
in MCF7 and SUM159 cells treated with the DRD2-specific agonist quinpirole. Both of these 
cell lines express DRD2 (Figure 3.3), however the tumorsphere formation of both lines is 
unaffected by thioridazine (Figure 3.1). Strikingly, the tumorsphere formation of both MCF7 
and SUM159 cells is dose-dependently increased by quinpirole treatment (Figure 3.5A and B). 
This suggests that functional DRD2 protein is indeed expressed, and can promote self-renewal 
when activated.  
3.2.4 Expression of Plasminogen Pathway Genes 
 Since expression of DRD2 cannot itself determine whether the self-renewal of a cell 
line is inhibited by thioridazine, we searched for gene expression differences between the 
breast cancer cell lines using microarray data (Prat et al., 2013). We especially searched for 
genes in pathways known to regulate dopamine receptors. Activation of the protease plasmin 
by tissue plasminogen activator (PLAT) or urokinase plasminogen activator (PLAU) promotes 
the release of dopamine from cultured neurons, and it is associated with breast cancer 
metastasis (Andreasen et al., 1997; Ito et al., 2006; Nagai et al., 2004, 2005).  
 We searched the microarray data for the expression of PLAT, since its expression 
supports dopamine release in neurons, and is associated with poor breast cancer outcomes. 
Further, we searched for the expression of the receptor for PLAU (PLAUR), which is required 
for PLAU to activate plasmin (Andreasen et al., 1997). We also probed the microarray data 
for expression of the plasminogen pathway inhibitor, PAI-1. Interestingly, the luminal and 




plasminogen activators and inhibitors (Figure 3.6A to C). If plasmin activation is not occurring 
in these cell lines, potentially little dopamine release may occur. While claudin-low cell lines 
(SUM159, MDA-MB-231, and HCC38) express more PLAT and PLAUR, SUM159 and MDA-MB-
231 cells also express high levels of the PAI-1 inhibitor of plasmin (Figure 3.6A to C). On the 
other hand, most of the basal-like cell lines express higher levels of either PLAT and/or PLAU, 
and generally lower levels of PAI-1 (Figure 3.6A to C). In this regard, we considered whether 
PAI-1 expression is generally increased in claudin-low cells and tumors compared with basal-
like cells and tumors. We probed the microarray data across many cell lines and human 
tumors, and we compared the PLAT, PLAUR, and PAI-1 expression between all basal-like 
samples and all claudin-low samples (Prat et al., 2013). Interestingly, while the expression of 
PLAT and PLAUR is similar, if not increased in claudin-low cells and tumors, the claudin-low 
cells and tumors express significantly elevated levels of PAI-1 (Figure 3.6D). These data 
suggest that the plasminogen pathway may be most active in the most thioridazine-sensitive 
cell lines, and could lead to DRD2 activity through the regulation of dopamine release. 
3.2.5 Activation of the plasminogen pathway promotes sphere formation and sensitivity to 
thioridazine 
 We addressed whether the plasminogen pathway has effects on DRD2-mediated 
tumorsphere formation in the MCF7 and SUM159 cell lines. We have shown that the 
tumorsphere formation activity of both of these cell lines is unaffected by thioridazine (Figure 
3.1A), yet they both express DRD2, and a DRD2 agonist can stimulate tumorsphere formation 
(Figure 3.3 and 3.5). Additionally, MCF7 cells express relatively low levels of the genes of the 
plasminogen activation system, while SUM159 cells express high levels of PLAT, an activator 
of plasminogen, but also high levels of PAI-1, the plasminogen inhibitor. Therefore, both cell 
lines likely have low plasminogen activation, but for different reasons. 
To test this, we overexpressed PLAT in MCF7 cells to activate the plasminogen system, 




treated with DMSO or 1µM thioridazine. After one week, the number of tumorspheres were 
counted. We observed that PLAT overexpression increased tumorsphere formation by 36% 
(Figure 3.7A). Interestingly, thioridazine treatment abrogated the induction of tumorsphere 
formation by PLAT overexpression (Figure 3.7A). We calculated the percent change in 
tumorsphere formation caused by thioridazine in control MCF7 cells, compared with PLAT 
overexpression cells. While 1µM thioridazine had no significant effect on tumorsphere 
formation in control cells, it decreased tumorsphere formation by approximately 30% in 
MCF7-PLAT cells (Figure 3.7B). This suggests that PLAT supports DRD2-mediated 
tumorsphere formation. 
To test whether the plasminogen pathway inhibitor PAI-1 inhibits DRD2-mediated 
tumorsphere formation in claudin-low cells, we cultured SUM159 cells transfected with 
siControl or siPAI-1 as spheres and treated them with DMSO or 1µM thioridazine. After 1 
week, the number of tumorspheres formed was quantified. PAI-1 knockdown alone, led to an 
increase in tumorsphere formation, while 1µM thioridazine alone had no effect on tumorsphere 
formation (Figure 3.7C). As observed in MCF7 cells, the increase in tumorsphere formation 
due to PAI-1 knockdown was abrogated by 1µM thioridazine treatment (Figure 3.7C). While 
1µM thioridazine had no effect on siControl SUM159 cells, it decreased tumorsphere formation 
by approximately 40% in siPAI-1 SUM159 cells (Figure 3.7D). Together, these data suggest 
that an active plasminogen pathway promotes tumorsphere formation in a DRD2-dependent 
mechanism. 
3.3 – Discussion 
 The work presented in this chapter shows that the self-renewal of basal-like breast 
cancer cell lines is more sensitive to thioridazine than that of other subtypes. This was shown 
by analyzing the effects of thioridazine on a panel of 11 breast cancer cell lines (Figure 3.1). 
Further, we used cell lines that were sorted into EpCAM+ and EpCAM- populations to show 




(EpCAM-) cells, despite the fact that the cells are derived from the same cell line (Figure 3.2). 
This suggests basal-like cell lines have a population of tumorsphere-initiating cells (TICs) that 
are maintained by the activity of DRD2, while cell lines with characteristics of other molecular 
subtypes do not. It important to note that basal-like breast cancers are the most sensitive to 
thioridazine, as there are no current targeted therapies for most basal-like breast tumors. It 
is also noteworthy that thioridazine targets basal-like TICs. Thioridazine is safe, cheap, and 
already FDA-approved. It could easily be added in addition to current breast cancer therapies 
to test whether it could reduce the recurrence or metastasis of basal-like breast cancers. 
We also demonstrated that DRD2 mRNA and protein is expressed in all cell lines, even 
if thioridazine does not affect tumorsphere formation (Figure 3.3). Further, treatment with 
the specific DRD2 agonist quinpirole increases tumorsphere formation in MCF7 and SUM159 
cells (Figure 3.5), despite the fact that thioridazine does not affect tumorsphere formation in 
these cell lines. This suggests that DRD2 is expressed in these cells, and that it is capable of 
supporting self-renewal, but that it is generally not active. We utilized previously published 
gene expression data to find pathways that may predict whether a cell line may be more 
sensitive to DRD2-inhibition (Prat et al., 2013). We found that basal-like cell lines, especially 
those most sensitive (SUM149, SUM229, and HCC1143) express high levels of plasminogen 
activating genes, while luminal cells expressed low levels, and claudin-low cells expressed 
high levels of the plasminogen inhibitor PAI-1 (Figure 3.6). This suggests that DRD2 may 
support self-renewal in cell lines that have higher activation of the plasminogen pathway. We 
tested this by overexpressing PLAT, the plasminogen activator, in MCF7 cells and treating 
with thioridazine. Thioridazine blocked the induction of tumorsphere formation induced by 
PLAT overexpression. Additionally, knockdown of PAI-1 in SUM159 cells also increased 
tumorsphere formation, in a thioridazine-sensitive manner (Figure 3.7). These data suggest 
that activation of the plasminogen system may support self-renewal in a DRD2-dependent 




activation in basal-like cell lines may support dopamine release and DRD2-supported self-
renewal (Figure 3.8A). On the other hand, lack of expression of plasmin activators in luminal 
cells prevents dopamine release and DRD2 activity (Figure 3.8B). Finally, the high expression 
of PAI-1 in claudin-low cells inhibits plasmin, which also results in dopamine not being 
released, and DRD2 inactivity (Figure 3.8C). 
Since plasminogen activation has been shown to promote dopamine release in neurons 
(Ito et al., 2006; Nagai et al., 2004, 2005), it is possible that the thioridazine-sensitive 
induction in tumorsphere formation caused by activation of this pathway may arise from 
dopamine release activating DRD2. However, while we have attempted to detect dopamine 
release in breast cancer cell lines, it has not yet been conclusively shown whether these cell 
lines can, in fact, release dopamine. It has also not yet been shown whether any human 
breast tumors release dopamine. This must be investigated further, as we have successfully 
detected dopamine from tumor tissue obtained from a triple-negative C3-Tag tumor (Figure 
3.9). Determining whether plasminogen activation supports the self-renewal of breast cancer 
cells may lead to new therapeutics.  Additionally, it possible that in vivo, that DRD2 inhibition 
may inhibit self-renewal in other types of cancer than just basal-like tumors. If DRD2 is 
expressed in many tumors, then any tumor that releases dopamine may benefit from DRD2 
inhibition. Dopamine release may come from nerve growth into the tumor, or from infiltrating 
immune cells, which have also been shown to release dopamine (Arreola et al., 2016; Levite, 
2016; Magnon et al., 2013; Zahalka et al., 2017). 
 The importance of the plasminogen pathway in determining breast cancer self-renewal 
should be tested further, especially whether the pathway activates DRD2 to support self-
renewal. The use of gene expression databases like the cancer cell line encyclopedia can be 
used to predict whether cell lines have high expression of genes of the plasminogen activation 
pathway. Then tumor-initiation assays can then be performed with cell lines predicted to have 




results from cell lines predicted to have low plasminogen pathway activation. This can be done 
using cells of many different cancer types, and would test whether plasminogen activation 
predicts whether the self-renewal of a cell line will be affected by thioridazine.  
3.4 – Experimental Procedures   
Cell culture and reagents 
SUM149, SUM159, SUM229, SUM149-EpCAM+/=, and SUM229 EpCAM+/- cells were 
maintained in HuMEC medium (Gibco, Waltham, MA, USA) with 5% fetal bovine serum (FBS). 
MDA-MB-231 cells were maintained in DMEM (Gibco) with 10% FBS. MCF7, ZR751, BT474, 
MDA-MB-361, HCC38, HCC1143, and HCC1937 cells were maintained in RPMI-1640 with 10% 
FBS. SUM229-EpCAM-sorted cells were generously provided by the lab of Dr. Gary Johnson. 
Thioridazine and quinpirole were obtained from (Sigma-Aldrich, St. Louis, MO, USA). All 
antibodies were obtained from Cell Signaling Technologies (Danvers, MA, USA). qPCR primer-
probe sets targeting GUSB were obtained from Applied Biosystems (Grand Island, NY, USA). 
DRD2 primer-probe set was obtained from Bio-Rad (Hercules, CA, USA). DRD2 antibody was 
obtained from Sigma-Millipore. β-actin antibody was obtained from Cell Signaling 
Technologies (Danvers, MA, USA). EpCAM-FITC antibody for flow cytometry and cell sorting 
was obtained from Stem Cell Technologies (Vancouver, BC, CA). All siRNAs were SMARTpool 
siGENOME from Dharmacon (Lafayette, CO, USA). PLAT overexpression plasmid in pLENTI6-
V5 vector was obtained from the CCSB - Broad lentiviral ORF collection (Yang et al., 2011). 
 
Transfections 
Overexpression of PLAT in MCF7 was achieved by transfecting 4µg of plasmid with 12µL 
of Fugene6 (Promega, Madison, WI, USA). siRNA transfections were achieved by using 40nM 






Tumorsphere assays were performed as previously described (Tegowski et al., 2018). 
Cells were trypsinized and resuspended into a single cell suspension and counted using a 
hemocytometer. 20000 cells were resuspended in 2 mL of complete mammocult medium 
(Stem Cell Technologies) and plated into ultra-low adherence 6 well plates (Corning, Corning, 
NY, USA). After one week of culture, the spheres were collected and all spheres greater than 
60μm in diameter were counted according to manufacturer’s protocol (Stem Cell 
Technologies). Transfection for overexpression and siRNA were completed 24 hours prior to 
plating in the tumorsphere assay. Thioridazine treatments were applied once at the time of 
plating. Quinpirole, was applied every 48 hours. Tumorsphere formation data in Figure 3.1A 
for SUM159, MDA-MB-231, HCC38, HCC1937, SUM149, and HCC1143 are taken from 
(Tegowski et al., 2018). 
 
Proliferation assays 
Proliferation assays for SUM149 and SUM159 were previously reported in (Tegowski 
et al., 2018). For all other cell lines, 10,000 cells per well were plated in 24 well plates in 
triplicate and treated with DMSO or the indicated concentration of thioridazine. After 72 hours, 
the number of cells per well was counted using a hemocytometer. 
 
Flow cytometry and sorting 
To perform flow cytometry analysis for EpCAM, cells were detached using TrpLE 
Express (Gibco) at 37°C. Cells were resuspended in full growth medium and counted using a 
hemocytometer. 500,000 cells were resuspended in flow buffer (PBS containing 1% FBS and 
1mM EDTA) and 2.5µL EpCAM antibody (Stem Cell Technologies) on ice for 45 minutes. Cells 
were washed once with flow buffer and fixed for 15 minutes at room temperature in PBS + 
10% Formalin. Cells were washed with flow buffer, passed through a 40µm filter, and then 




USA) and analyzed using FloJo software (Ashland, Oregon, USA). To sort SUM149 cells by 
EpCAM expression, cells were detached using TrpLE Express (Gibco) at 37°C. Cells were 
resuspended in full growth medium and counted using a hemocytometer. 107 cells were 
counted and resuspended in 900µL HBSS (Gibco) + 100µL 10x Buffer + 50µL DNAse I 
(Promega) at room temperature for 15 minutes. Cells were washed with flow buffer and 
resuspended in 1mL flow buffer and treated incubated on ice with 50µL EpCAM antibody for 
45 mintues. Cells were washed with flow buffer, passed through a 40µm filter, and then sorted 
using a FACS Aria II (Becton Dickinson). Cells were then cultured at high density for 24 hours. 
Cells were cultured for at least 96 hours prior to be used for experiments. 
 
Quantitative PCR 
RNA isolation and quantitative PCR 
Total RNA was isolated using Trizol (Invirogen) according to manufacturer’s protocol. 
iScript (Bio-Rad) was used to make cDNA. Quantitative PCR was performed with iTaq Probes 
Supermix (Bio-Rad) using a Viia 7 qPCR machine (Applied Biosystems, Foster, CA, USA) and 




Immunoblots were performed as previously described (Tegowski et al., 2018). 
 
Dopamine ELISA 
C3-Tag tumor tissue was obtained as a gift from the UNC Mouse Phase I Facility. Tumor 
samples were frozen at -80°C until just before the ELISA was performed. The tumor section 




PBS/100mg tumor tissue. The ELISA was performed according to manufacturer’s instruction 
(Biovision, Milpitas, CA, USA). 
 
Statistics 


















Figure 3.1 - Thioridazine preferentially targets the tumorsphere initiating cells of 
basal-like breast cancer cell lines (BLBCLs) (A) Cells were cultured in a tumorsphere 
assay with DMSO, 1μM, 2μM, or 5μM thioridazine. The number of tumorspheres formed after 
one week were counted. Tumorsphere formation is shown as fold-change relative to DMSO. 




reported (Tegowski et al., 2018). (B) Cells were plated and treated with DMSO, 1μM, 2μM, or 
5μM thioridazine. The number of cells were counted after 72 hours. The fold-change in cell 
number relative to DMSO is shown. Data for SUM159 and SUM149 was previously reported 
(Tegowski et al., 2018). All experiments where performed with three biological replicates. 
Significance was measured using a one-sample t-test. Error bars represent standard 

















Figure 3.2 - Thioridazine preferentially targets the tumorsphere initiating cells of 
the basal-like population within the same cell line. (A) SUM229-EpCAM+ and SUM229-
EpCAM- cells were cultured in a tumorsphere assay with DMSO, 1μM, 2μM, or 5μM 
thioridazine. The number of tumorspheres formed after one week were counted. 
Tumorsphere formation is shown as fold-change relative to DMSO. (B) SUM229-EpCAM+ and 
SUM229-EpCAM- cells were plated and treated with DMSO, 1μM, 2μM, or 5μM thioridazine. 
The number of cells were counted after 72 hours. The fold-change in cell number relative to 
DMSO is shown. (C) The EpCAM expression of SUM229-EpCAM+ and SUM229-EpCAM- cells 
was determined using flow cytometry to check for the purity of the populations. (D) 
SUM149-EpCAM+ and SUM149-EpCAM- cells were cultured in a tumorsphere assay with 




were counted. Tumorsphere formation is shown as fold-change relative to DMSO. (E) 
SUM149-EpCAM+ and SUM149-EpCAM- cells were plated and treated with DMSO, 1μM, 2μM, 
or 5μM thioridazine. The number of cells were counted after 72 hours. The fold-change in 
cell number relative to DMSO is shown. (F) The post-sort EpCAM expression of SUM149-
EpCAM+ and SUM149-EpCAM- cells was determined using flow cytometry to check for the 
purity of the populations. (A to B) and (C to D) where performed with three biological 
replicates. Significance was measured using a one-sample t-test. Error bars represent 




























Figure 3.3 - DRD2 expression does not predict thioridazine effects on self-renewal. 
(A) Total RNA was harvested from all cell lines in the 11-cell line panel. DRD2 expression 
normalized to GUSB was determined by qPCR, and displayed relative to the expression of 




(HCC1937, HCC1143, SUM149, and SUM229) was compared to the average DRD2 expression 
in the other 7 cell lines. (B) Total RNA was harvested from the 11-cell line panel. DRD2 
expression normalized to GUSB was determined, and displayed relative to the expression of 
SUM149. (C) Total RNA was harvested from SUM229-EpCAM+ and SUM229-EpCAM- cells. 
DRD2 expression normalized to GUSB was determine, and displayed relative to the expression 
in SUM229-EpCAM+ cells. (D) Total RNA was harvested from SUM149-EpCAM+ and SUM149-
EpCAM- cells. DRD2 expression normalized to GUSB was determine, and displayed relative to 
the expression in SUM149-EpCAM+ cells. (E) Cells from the indicated cell lines were harvested 
and total DRD2 protein was determined by immunoblot. (F) Quantification of DRD2 protein 
normalized to actin. All experiments where performed with three biological replicates except 















































Figure 3.4 – Confirming the specificity of the DRD2 antibody – SUM229-EpCAM+ cells 
were treated with siControl or siDRD2 for 72 hours. Then cells were harvested, lysed, and 




















Figure 3.5 – Quinpirole increases tumorsphere formation in MCF7 and SUM159 cells. 
(A) MCF7 cells were cultured in a tumorsphere assay and treated with the indicated 
concentrations of quinpirole every 48 hours. After 7 days, the number of tumorspheres formed 
was counted. Tumorsphere formation is shown as fold-change relative to DMSO. (B) SUM159 
cells were cultured in a tumorsphere assay and treated with the indicated concentrations of 
quinpirole every 48 hours. After 7 days, the number of tumorspheres formed was counted. 
Tumorsphere formation is shown as fold-change relative to DMSO. All experiments where 
performed with three biological replicates. was measured using a one-sample t-test. Error 





























Figure 3.6 – Expression of plasminogen pathway genes in breast cancer cell lines 
and tumors. (A) The normalized expression of PLAT from microarray data reported in (Prat 
et al., 2013) in the indicated cell lines. (B) The normalized expression of PLAUR from 
microarray data reported in (Prat et al., 2013) in the indicated cell lines. (C) The normalized 
expression of PAI-1 from microarray data reported in (Prat et al., 2013) in the indicated cell 
lines. (D) The normalized expression of PLAT, PLAUR, and PAI-1 in all basal-like and claudin-















Figure 3.7 – Activation of the plasminogen pathway supports DRD2-mediated 
tumorsphere formation. (A) Control and PLAT-overexpressing MCF7 cells were plated in a 
tumorsphere assay and treated with DMSO or 1µM thioridazine. After 7 days, the number of 
tumorspheres were counted. Tumorsphere formation is shown as fold-change relative to 
DMSO control. (B) The fold-change in tumorsphere formation caused by 1µM thioridazine 




1 treated SUM159 cells were plated in a tumorsphere assay and treated with DMSO or 1µM 
thioridazine. After 7 days, the number of tumorspheres were counted. Tumorsphere formation 
is shown as fold-change relative to DMSO control. (D) The fold-change in tumorsphere 
formation caused by 1µM thioridazine treatment is shown for siControl and siPAI-1 treated 
SUM159 cells. (E) The expression of PLAT was determined by qPCR in control and PLAT-
overexpressing MCF7 cells. (F) The expression of PAI-1 was determined by qPCR in siControl 
and siPAI-1 treated SUM159 cells. All experiments where performed with three biological 
replicates. Significance for (A) and (C) was measured using a one-sample t-test. Significance 
for (B) and (D) was measured using a two-sample t-test. Error bars represent standard 















































Figure 3.8 – Model figure depicting the hypothesis that the plasminogen pathway 
promotes tumorsphere formation in basal-like breast cancer cells by regulating 




the release of dopamine and DRD2 activation, leading to tumorsphere formation via STAT3. 
(B) Luminal cell lines express low levels of plasminogen activators, and therefore may not 
release much dopamine, and therefore have inactive DRD2. (C) Claudin-low cell lines may 
express high levels of PAI-1, the plasmin inhibitor, and therefore not release much dopamine, 




















































Table 3.1 – Dopamine detection in a C3-Tag tumor. C3-Tag tumor tissue was 
homogenized and an ELISA for dopamine was performed with the extract. The result shown 
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CHAPTER 4: CONCLUSIONS AND FUTURE STUDIES 
4.1 – Conclusions and Discussion 
Although thioridazine, as well as another DRD2-targeting antipsychotic pimozide, were 
shown to decrease the proliferation of cultured cancer cells nearly 30 years ago (Strobl and 
Peterson, 1992; Strobl et al., 1990), the effects of these drugs had been largely ignored until 
Sachlos et al discovered thioridazine in a small molecule screen for differentiation-inducing 
compounds (Sachlos et al., 2012). That study showed that thioridazine could induce cellular 
differentiation and cause a greater reduction in colony formation of AML blasts than of normal 
hematopoietic stem cells. They showed that this inexpensive compound, which is already 
FDA-approved for treating schizophrenia, could reduce CSC-like activity, without inhibiting 
normal stem cells. Several studies following the Sachlos et al publication confirmed that higher 
doses of thioridazine (5-20µM) induces cell cycle arrest and apoptosis (Cheng et al., 2015; 
Meng et al., 2016; Yin et al., 2015; Zhang et al., 2016). However, the roles of DRD2, the 
primary target of thioridazine, have largely gone unexplored. It is important to determine 
whether thioridazine (or other antipsychotics that inhibit cancer cell growth or self-renewal) 
are actually working through dopamine receptor inhibition, because even though thioridazine 
binds and inhibits DRD2 with high affinity, it is also known to bind other GPCRs with high 
affinity, including some serotonin receptors and adrenergic receptors (Besnard et al., 2012). 
Therefore, it must be experimentally determined whether any observed effects of thioridazine 
are via DRD2 inhibition, as opposed to the inhibition of other receptors. This is especially 
important since compounds targeting serotonin receptors, which are also known to bind 
DRD2, have also been shown to induce cell cycle arrest and apoptosis of cancer cells, as well 
as possibly targeting CSCs (Gwynne et al., 2017; Hallett et al., 2014). 
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Work presented in this thesis shows that, although thioridazine indeed induces a cell 
cycle arrest and potentially apoptosis at higher doses (5-10µM) in all breast cancer cell lines 
tested, this activity is independent of DRD2 (Chapter 2, Figure 4.1). Conversely, the reduction 
in tumorsphere formation observed when cells are treated with lower doses of thioridazine 
(1-2µM), does work through DRD2 inhibition. This suggests that in breast cancer cells, DRD2 
is not required to maintain cell survival or cell cycle progression, but that a subset of 
tumorsphere-initiating cells (TICs) are supported by the activity of DRD2. These DRD2-
supported TICs are not present in all breast cancer cell lines, however. We tested the effects 
of thioridazine on tumorsphere formation in luminal, HER2+, claudin-low, and basal-like 
breast cancer cell lines, and DRD2 only supported TICs in the basal-like cell lines (Chapter 2 
and 3). This discrepancy in sensitivity suggests that, if translated clinically, some patients 
would likely benefit from DRD2-targeting therapies more than others.  
We also showed that DRD2 promotes tumorsphere formation by supporting a 
STAT3/IL-6 feedforward loop in SUM149 cells (Chapter 2, Figure 4.1). Our work suggests that 
DRD2 activity does not activate STAT3 by supporting IL-6 receptor signaling, but instead, IL-
6 is downstream of DRD2 and IL-6 can rescue tumorsphere formation defects of DRD2 
knockdown cells (Chapter 2). Although we have shown that thioridazine treatment reduces 
active phosphorylated JAK2 (Figure 4.2), it remains uncertain what mechanisms may underlie 
this regulation. Work from Hua Yu’s laboratory showed that another GPCR, S1P1R, can 
promote STAT3 activation in bladder cancer cells through direct binding of JAK and Src (Lee 
et al., 2010). DRD2 has also been shown to activate membrane-associated proteases, which 
release heparin-bound epidermal growth factor, thereby inducing EGFR activity (Yoon and 
Baik, 2013), which has been shown to promote STAT3 activation via Src (Silva, 2004). If 
DRD2 support of STAT3 activity is found to be a general mechanism observed in a variety of 




 Since we noticed that thioridazine could reduce the formation of tumorspheres in 
some triple-negative breast cancer cell lines, but not others (Figure 2.2), we investigated 
which breast cancer cells’ self-renewal was most sensitive to thioridazine. Interestingly, the 
self-renewal of basal-like cells are uniquely sensitive to thioridazine, compared to cells of 
other subtypes (Figure 3.1). Further, the basal-like cells express more DRD2 mRNA, on 
average, than cells of other subtypes, suggesting that high DRD2 levels may explain why 
basal-like cells are more sensitive to DRD2 inhibition (Figure 3.3). However, SUM149 cells, 
which are highly sensitive to thioridazine, express relatively low levels of DRD2, while 
HCC1937 cells, which are only modestly affected by thioridazine, express the most DRD2 
mRNA of all the cell lines in the panel (Figure 3.3). This suggests that DRD2 expression alone 
does not predict whether TIC-activity within a cell line is supported by DRD2. Importantly, we 
also demonstrated that treatment with quinpirole, a selective DRD2 agonist, promotes 
tumorsphere formation in two cell lines (SUM159 and MCF7) in which thioridazine does not 
reduce tumorsphere formation (Figure 3.4). These data suggest that these thioridazine-
insensitive cell lines express DRD2, that DRD2 is capable of supporting TIC-activity, but that 
DRD2 is not being activated. Presumably this is due to a lack of dopamine production or 
release, but that is not yet conclusively known. ONC201 is a small molecule in currently in 
clinical trials that, like thioridazine, is thought to be a DRD2 inhibitor (Madhukar et al., 2017), 
yet has strong anticancer effects that are not dependent on DRD2 activity (Kline et al., 2018). 
High expression of DRD5 has been shown to correlate with resistance to ONC201 (Prabhu et 
al., 2019). The possibility of antagonism or compensation from other dopamine receptors 
should also be investigated with thioridazine and other DRD2-targeting anticancer 
compounds. 
It is presently unclear whether any of these breast cancer cell lines release dopamine, 
let alone whether the more highly sensitive basal-like cell lines actively release more 
dopamine than the cell lines of other subtypes. However, that is a question we are interested 
in addressing. For now, the observed effects of the components of the plasminogen pathway 
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components do imply that some cell lines may release more dopamine than others. The 
plasminogen pathway is well studied for its roles in thrombosis, and treatment with activators 
of plasminogen, particularly tPA, can be used to degrade blood clots during ischemia (Adams 
et al., 2007). However, the activators (PLAT/tPA, PLAU/uPA, and PLAUR/uPAR) and the 
inhibitor (SERPINE1/PAI-1) of plasminogen are correlated with breast cancer metastasis and 
decreased survival in breast cancer patients (Li et al., 2018; Mekkawy et al., 2014; Schmitt 
et al., 2011; Smith and Marshall, 2010). Along those lines, we have shown that expression of 
PLAT, PLAUR, and/or PAI-1 are highest in claudin-low and basal-like cell lines (Figure 3.5). 
Not only does plasminogen pathway biology support breast cancer metastasis, but it also 
been shown to support the release of dopamine in cultured neurons (Ito et al., 2006; Nagai 
et al., 2004, 2005; Samson and Medcalf, 2006). In fact, ablation of the PLAT gene can 
eliminate depolarization-induced dopamine release, but treatment with recombinant plasmin 
can rescue that effect (Ito et al., 2006). This suggests that perhaps DRD2 would be most 
active in supporting self-renewal of cells in which the plasmin pathway is most active, 
supporting the release of dopamine. 
We tested this hypothesis by expressing PLAT, the gene that produces tPA, in MCF7 
cells. Tumorsphere formation of MCF7 cells is not affected by thioridazine (Figure 3.1), and 
MCF7 cells express relatively low levels of both activators and inhibitors of the plasminogen 
pathway (Figure 3.5). We reasoned that PLAT overexpression may be able to support 
plasminogen activation and subsequent dopamine release, increasing tumorsphere formation 
in a manner that should then be thioridazine sensitive. Remarkably, that is what we observed 
(Figure 3.6). To further test whether the plasminogen pathway supports DRD2-dependent 
self-renewal, we used siRNA to knockdown PAI-1 expression in SUM159 cells. Tumorsphere 
formation in SUM159 cells is also not affected by thioridazine, and although they express 
relatively high levels of PLAT, they also express high levels of PAI-1, the inhibitor. So we 
reasoned that if expression of the inhibitor was released, tPA could be more active and support 
increased tumorsphere formation, again in a thioridazine-sensitive manner. Indeed, that is 
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what we observed (Figure 3.6). Together, these data tentatively suggest that the plasminogen 
activation system can support DRD2-dependent self-renewal. However, it remains critical to 
measure whether this activity is mediated through the regulation of dopamine release, or 
possibly, an unrelated mechanism. 
 Although we have found that thioridazine inhibits self-renewal in a DRD2-dependent 
manner most strongly in basal-like breast cancers, it is possible that DRD2 inhibition may 
have an effect on other tumor types in vivo. First, many groups have shown that doses of 
thioridazine greater than 5-10µM are broadly cytotoxic (Johannessen et al., 2018; Sachlos et 
al., 2012; Strobl and Peterson, 1992; Tegowski et al., 2018; Yin et al., 2015; Yin et al., 2015; 
Yue et al., 2016). Therefore, treatment with high, yet tolerable, doses of thioridazine could 
complement chemotherapy and reduce tumor size (Luo et al., 2016; Yin et al., 2015), even 
if self-renewal is not specifically affected. The mechanisms by which thioridazine leads to cell 
cycle arrest and apoptosis are important consequences of thioridazine treatment that need 
further elucidation. Also, our data suggest that basal-like breast cancer cell lines both express 
and activate DRD2 signaling. However, if dopamine release is the cause of DRD2 activation, 
then any tumor that expresses DRD2 could potentially have a population of TICs maintained 
in a DRD2-dependent manner. This is because the complex tumor microenvironment can 
harbor cell types that are capable of synthesizing and releasing dopamine. 
 Dopamine can be synthesized by immune cells, including B cells, T cells, and 
macrophages (Arreola et al., 2016; Levite, 2016). This indicates that in the in vivo tumor 
microenvironment, infiltrating immune cells, some of which have already been shown to 
support tumor growth and metastasis (Grivennikov et al., 2010), may synthesize and release 
dopamine, even if the tumor cells are not. Additionally, dopamine may promote the 
polarization of macrophages towards the M2 type (Haskó et al., 1996) and promote the 
polarization of activated T cells to the Th2 state, rather than the Th1 (Figure 4.3) (Levite, 
2016; Nakano et al., 2009). Both M2 and Th2 macrophages and T cells are associated with 
cancer progression, metastasis, and immune evasion (Grivennikov et al., 2010). Therefore, 
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the use of dopamine receptor antagonist may be able to modulate the tumor 
microenvironment, making it less amenable to tumor growth and metastasis, even if the 
tumor cells themselves do not express dopamine receptors or produce dopamine. However, 
this has not yet been conclusively shown, and instead is a potentially important area of future 
investigation. Even further, work in prostate cancer has shown that neurons can extend into 
the tumor boundaries and support growth via adrenergic receptors (Magnon et al., 2013; 
Zahalka et al., 2017). This suggests that innervation of dopaminergic neurons may be 
possible, which then could release dopamine into the tumor milieu.  
 The work presented in this thesis contributes to a growing field, and there is evidence 
that thioridazine, or other DRD2-targeting agents, may have therapeutic effects in cancer. 
However, many important questions remain unaddressed. Further studies addressing the 
impacts of antipsychotics in cancer, the roles of dopamine receptors, and even roles of other 
neurotransmitter receptors in cancer may lead to new, safe, and cheap therapies for patients. 
4.2 – Future Directions 
 While there are many potential avenues to explore the effects of antipsychotics and 
the roles for dopamine receptors in cancer, there are several important areas that have 
received little attention.  
First, the source of dopamine receptor activation remains elusive. Dopamine released 
into the tumor microenvironment is presumed to be the most likely source of dopamine 
receptor activation. However, the measurement of dopamine in tumor tissue and tumor cells 
has received little attention, with one exception. Pheochromocytoma tumors, which arise from 
dopamine-producing cells in the adrenal gland (Lenders et al., 2005). Released dopamine, 
epinephrine, and norepinephrine (catecholamines) can cause dangerous side effects, but the 
release of catecholamines is not thought to be the dominant driver of tumor growth. Instead 
many patients have mutations in the hypoxia-inducible factor (HIF) pathway, or in the 
succinate dehydrogenase complex, mutations in which leads to HIF activation (Kantorovich et 
al., 2010). In order to test whether dopamine release is occurring in other cancer types, HPLC 
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can be used on samples obtained from tumor tissue, conditioned cultured cell medium, and 
conditioned organoid medium. Additionally, orthotopic mouse tumor models such as 4T1 can 
be used to genetically probe the effects of dopamine receptors in both tumor tissue and non-
tumor tissue. 4T1 is an especially promising model as it is a triple-negative breast cancer 
model, and its growth is reduced by thioridazine treatment (Yin et al., 2015). To test whether 
DRD2 has functions in the tumor microenvironment, wild-type 4T1 tumors can be grown 
orthotopically in DRD2-/- mice. Tumor growth, as well as metastatic frequency or tropism can 
then be measured. If differential growth or metastasis is observed in DRD2 knockout mice, 
the effects be further investigated using inducible knockouts induced by tissue-specific 
expression of cre-recombinase. Similarly, the origins and effects of dopamine can be studied 
by using tyrosine hydroxylase (TH) knockout mice. Tyrosine hydroxylase is the enzyme that 
catalyzes the rate-limiting step in dopamine synthesis. Since homozygous TH knockout mice 
do not reach adulthood (Kobayashi et al., 1995), tissue-specific deletions will be required. 
However, much can be learned from the growth of TH-deleted tumor cells, or from tumors 
grown in mice that have TH deleted from leukocyte or lymphocyte populations. 
Detection of dopamine in tumor tissue is critical to understanding the effects of 
dopamine receptors on tumor growth. However, a report that Wnt5a, a non-canconical Wnt-
family member, can bind DRD2 and affect neurite outgrowth in a DRD2-dependent manner 
(Yoon et al., 2011) suggests the possibility that factors other than dopamine may activate 
DRD2 signaling in tumors. Further, Wnt5a is known to promote EMT in breast cancer cells 
(Jordan et al., 2013), as well as the increase the production of dopaminergic neurons from 
neural stem cells (Parish et al., 2008). These data suggest that Wnt5a may be to able 
functionally activate DRD2 and affect the tumorigenicity of breast cancer cells. 
Another major area of need is to determine the molecular mechanisms of the effects 
of thioridazine and other antipsychotics on cancer cells. It is especially important to 
investigate the molecular effects of dopamine receptor inhibition on self-renewal pathways. 
To accomplish this, cells should ideally be cultured as spheres to enrich for TICs, a highly 
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sensitive cell line should be compared with a similar but insensitive cell line (SUM229 EpCAM+ 
compared to SUM229 EpCAM-), and low doses of thioridazine should be used (1-2µM). If 
SUM229 EpCAM+ and SUM229 EpCAM- cells are grown in sphere culture, treated with 1µM 
thioridazine, and total RNA harvested after 1-4 hours for RNAseq, then changes in gene 
expression patterns can be analyzed. This experiment should provide evidence of gene 
expression changes regulated by DRD2 in order to promote self-renewal, especially by directly 
comparing the thioridazine-induced changes in the EpCAM+ cells to the EpCAM-. We predict 
that STAT3-target genes would be affected (discussed in Chapter 2). However, other potential 
pathways may be elucidated. 
Proteomics approaches can also be used to elucidate mechanisms of DRD2 activity, 
especially within basal-like breast cancer cells. Expression of DRD2 fused to a mutated biotin 
ligase (BirA) will label any protein sequences that come into close proximity with biotin (Roux 
et al., 2012). Then the biotinylated proteins can be isolated and analyzed by mass 
spectrometry. If this experiment is done in SUM229 EpCAM+ tumorspheres treated with 1µM 
thioridazine, and compared with SUM229 EpCAM- tumorspheres treated with 1µM thioridazine, 
then downstream signaling components interacting with DRD2 can be identified. Ideally, this 
experiment can be compared with data from the RNAseq experiment described above to 
identify important signaling pathways regulated by DRD2 that support the self-renewal of 
TICs through changes in gene expression patterns. 
Although thioridazine, as well as other DRD2-targeting antipsychotic drugs, have been 
shown to have strong anti-cancer effects, there are still many important questions 
unanswered. Addressing these questions and learning more about how these inhibitors work, 








Figure 4.1 – A model figure of effects of thioridazine on breast cancer cells. 
In cells of all subtypes, 5µM thioridazine reduces proliferation through a mechanism that does 
not depend on DRD2. In basal-like breast cancer cells, thioridazine can inhibit self-renewal in 






Figure 4.2 – Thioridazine inhibits JAK2 activation. (A) SUM149 cells were cultured as 
tumorspheres for 1 week before treated with 1µM thioridazine for 15 minutes to 1 hour. The 
spheres were harvested, and immunoblots for pJAK2 (Y1007/1008), total JAK2, and actin 
were performed. (B) Quantification of the relative ratio of pJAK2/JAK. Experiment was 
performed in biological triplicate. Error bars represent standard deviation. Significance was 









Figure 4.3 – Potential effects on tumor-associated immune cells if dopamine 
signaling is disrupted. Dopamine release during T cell activation can shift T cells toward a 
Th2 polarization, which is less inflammatory and associated with promoting metastasis in a 
tumor setting. DRD2 activity can inhibit the production of M1-macrophage-associated genes, 
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